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ABSTRACT 
 
Transporters play a major role in the absorption and disposition of 
fexofenadine, suggesting this drug could be used as a probe of transporter 
activity.  When fexofenadine was administered in combination with four drugs 
(buspirone, caffeine, dextromethorphan and losartan) used to probe cytochrome 
P450 (CYP) activities, a significant decrease in fexofenadine AUC was observed 
without a change in elimination.  Based on this observation, I hypothesized a 
fexofenadine-probe drug interaction was occurring during oral absorption, and 
that this interaction was occurring at an enterocyte-expressed OATP.  This 
interaction was reproduced and studied using in vitro model systems. 
 
In Specific Aim 1, a specific LC-MS/MS method was developed and 
validated for the quantification of fexofenadine and the other four probe drugs for 
use in the remaining specific aims.  In Specific Aim 2, the interaction between 
fexofenadine and four enterocyte- and hepatocyte-expressed OATPs was 
characterized, and OATP1A2 was identified as the most effective transporter of 
fexofenadine, with a Km of 35 µM.  Because fexofenadine was efficiently 
transported by OATP1A2, the four CYP probe drugs were tested as inhibitors of 
OATP1A2-mediated fexofenadine transport in Specific Aim 3.  Buspirone, 
losartan, and dextromethorphan each inhibited OATP1A2-mediated fexofenadine 
transport in a concentration dependent manner. This inhibition could explain the 
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decrease in fexofenadine oral bioavailability seen in the clinical study we had 
previously conducted.  The replication of the fexofenadine-probe drug interaction 
in this model system supports the conclusion that OATP1A2 is the major uptake 
transporter for fexofenadine absorption in the enterocyte, and suggests that 
fexofenadine may be an effective probe drug for this transporter.  In Specific Aim 
4, I further characterized the fexofenadine-probe drug interactions using the three 
known OATP1A2 polymorphisms: Ile13Thr, Arg168Cys, and Glu172Asp.  While 
the mutants functioned as expected with regard to fexofenadine transport, the 
presence of the mutation did not alter the observed drug-drug interactions seen 
previously with OATP1A2 and the CYP probes.  Taking these data into account, 
it appears the fexofenadine-drug interaction seen previously is not affected by 
single nucleotide polymorphisms.  
 
This work demonstrates that OATP1A2 is capable of transporting 
fexofenadine and that several CYP probe drugs inhibit its transport by OATP1A2.  
This latter observation limits the utility of fexofenadine to be used as a single 
probe, rather than as part of a probe drug cocktail.
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Chapter 1 
Background and Significance 
 
Variability in drug response is a major clinical challenge that needs to be 
managed.  Pharmacokinetics often contributes significantly to variability in drug 
response.  There are two types or sources of variability in drug pharmacokinetics:  
between-subject or inter-individual variability and within-subject or intra-individual 
variability.  Sources of inter-individual variability in drug pharmacokinetics may 
include genetic differences in drug metabolism, environmental factors, gender, 
age, and the presence of disease, whereas intra-individual variability in drug 
response can often occur as a result of hormonal changes, physiologic changes 
due to disease progression, or, more commonly, as a result of interactions with 
drugs or other chemicals.  Experimental approaches to detect and investigate 
mechanisms of such variability in pharmacokinetics are essential tools for 
understanding, predicting, and managing such pharmacokinetic variability, and 
variability in drug response. 
 
1.1: Probe Drugs and Probe Drug Cocktails 
 
 The use of probe drugs for measuring enzyme and transporter 
activity in vitro and in vivo is a valuable tool for the study of variability in 
pharmacokinetics (Rendic et al., 1997; Bjornsson et al., 2003; Petsalo et al., 
2008).  Safe, well-characterized, and validated probe drugs for many of the key 
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cytochrome P450s (CYPs) are available and in use (Frye et al., 1997; Streetman 
et al., 2000; Zhu et al., 2001, Christensen et al., 2003; Ryu et al., 2007).  
However, specific probe drugs for Phase 2 drug metabolizing enzymes or for 
transporters are not well-characterized nor are they routinely used.  Probe drugs 
may be used individually; however the combination of multiple probe drugs into 
cocktails offers practical advantages, and now, becoming a more common 
approach.  Compared to the administration of single probe drugs in multiple 
studies, the co-administration of multiple probes as a cocktail for drug 
metabolizing enzymes offers a more efficient mode of studying drug disposition 
and drug-drug interactions in humans (Breimer et al., 1990; Frye et al., 1997; 
Streetman et al., 2000; Zhu et al., 2001, Christensen et al., 2003; Ryu et al., 
2007).  Obvious advantages are minimizing the influence of inter-individual and 
intra-individual variability to drugs over time and the reduced cost of human 
subject studies.  A probe drug cocktail containing buspirone, caffeine, 
dextromethorphan, and losartan was developed and used in a clinical study to 
examine the metabolic activities of CYPs in human subjects.  As a novel 
approach, fexofenadine, which is not metabolized, was included as a fifth drug to 
assess its utility in characterizing membrane transporter functions in these 
human subjects. 
 
Membrane transporters are proteins that transport drugs across cellular 
membranes and play an integral role in the absorption, distribution, metabolism, 
and excretion of drugs.  Due to their important role in absorption and disposition, 
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changes in transport activity can ultimately result in alteration of the 
pharmacokinetics of drugs (Giacomini, et al, 2010; Müller et al, 2011; Zhang et 
al., 2011).  A useful tool to study the role of transporters in vivo is the use of 
probe drugs.  Fexofenadine, a safe, well-tolerated and approved drug, has been 
used as a probe of transporter activity both in vitro as well as in vivo.  However, 
there is still uncertainty with regards to which membrane transporters influence 
fexofenadine pharmacokinetics and to what extent (Wang et al., 2002; Kharasch 
et al., 2005; Yasui-Furukori et al., 2005; Shimizu et al., 2006; van Heeswijk et al., 
2006; Bailey et al., 2007; Glaeser et al., 2007; Robertson et al., 2008).  Thus, it is 
critical to fully characterize the roles of various human transporters involved in 
fexofenadine pharmacokinetics and delineate their exact contributions, thus 
defining the utility of fexofenadine as a probe drug. 
 
1.2: Components of The Kansas Cocktail 
 
 Probe drugs are pharmaceutical compounds that are often used as 
biomarkers of enzyme or transport activity.  Probe drugs have been well defined 
for analyzing specific cytochrome P450 drug metabolizing enzymes but are not 
well established for assessing the role of membrane transporters in human 
subject studies.  The Kansas Cocktail was designed and validated to assess the 
function of four key drug-metabolizing CYPs and to assess transporter function 
(Reed et al., 2010).  The individual probe drugs and their targets are described 
and their structures are depicted in Figure 1.1. 
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1.2.1: Buspirone 
 
 Buspirone hydrochloride is an anti-anxiety agent that is not chemically or 
pharmacologically related to the benzodiazepines, barbiturates, or other 
sedative/anxiolytic drugs; it acts as a partial agonist at the 5-HT1A receptor 
(Yocca, 1990).  Although buspirone is almost entirely absorbed after oral 
administration, extensive first pass metabolism reduces its oral bioavailability to 
about 5% (Gammans et al., 1986).  The principal route of metabolism of 
buspirone leads to the formation of its major metabolite, 1-pyrimidylpiperazine, 
which is present in plasma at a concentration higher than the parent compound 
(Jajoo, 1989).  In vivo drug interaction studies have shown that the relative 
bioavailability of buspirone is increased by 3- to 19-fold by several well 
established CYP3A4 inhibitors, which suggests that buspirone is primarily 
metabolized by CYP3A4 (Kivistö et al., 1997; Lamberg et al., 1998; Laine et al., 
2003).  Accordingly, buspirone has been accepted an appropriate probe of 
CYP3A4 activity by the U.S. Food and Drug Administration (FDA 1999). 
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Figure 1.1: 
 
 
The Kansas Cocktail.  The five components of the Kansas cocktail are 
buspirone (A), caffeine (B), fexofenadine (C), dextromethorphan (D), and 
losartan (E).  Buspirone is a probe for CYP3A4, caffeine is a probe for CYP1A2, 
fexofenadine is a probe for transporter activity, dextromethorphan is a probe for 
CYP2D6, and losartan is a probe for CYP2C9. 
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1.2.2: Caffeine 
 
Caffeine is often used as a probe for CYP1A2 activity and was included in 
the probe drug cocktail for this purpose.  The major metabolites of caffeine are 1-
methylurate, 1-methylxanthine, 1, 7-dimethylurate, and 5-acetylamino-6-
formylamino-3-methyluracil.  Caffeine urinary metabolite ratios provide indices for 
activity of CYP1A2, and also of N-acetyltransferase (Frye et al., 1997; Scott et 
al., 1999; Streetman et al., 2000; Christensen et al., 2003; Ryu et al., 2007). 
Since direct measurement of caffeine clearance is cumbersome, the 
measurement of metabolite ratios of caffeine has been used instead as a 
noninvasive and easy way of indirectly assessing CYP1A2 activity (Peng et al., 
2004). 
 
1.2.3: Dextromethorphan 
 
Dextromethorphan is a synthetic, non-narcotic, centrally-acting cough 
suppressant.  The anti-tussive effectiveness of dextromethorphan has been 
demonstrated in both animal and human clinical studies and the incidence of 
toxic effects has been remarkably low.  Dextromethorphan is rapidly absorbed 
from the gastrointestinal tract after oral administration (Moghadamnia et al., 
2003).  Dextromethorphan undergoes rapid and extensive first-pass metabolism 
mainly through the action of CYP2D6; the bioavailability of oral 
dextromethorphan ranges from 1 to 2% in subjects who are extensive 
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metabolizers and approximately 80% in those who are poor metabolizers (Capon 
et al., 2006).  Its major metabolite is dextrorphan; allowing the ratio of 
dextrorphan/dextromethorphan to be used as a measure of CYP2D6 activity (Yu 
and Haining, 2001).  CYP2D6 is a highly polymorphic gene with more than 100 
known allelic variants (Abduljalil et al., 2010).  Because the overall disposition of 
dextromethorphan is highly dependent on CYP2D6 activity, these polymorphisms 
are the main source of the wide inter-individual variation in the plasma levels 
attained and the response elicited by dextromethorphan (Gaedigk et al., 2008). 
 
1.2.4: Losartan 
 
Losartan is an angiotensin II receptor antagonist (Type AT1) used to treat 
hypertension (Timmermans et al., 1993).  It is primarily converted to its active 
metabolite E3174 by CYP2C9 in the liver (Stearns et al., 1995; Yun et al., 1995) 
and the metabolite is primarily excreted into bile (Dickson et al., 2003).  Other 
sartan drugs such as valsartan and telmisartan are substrates of liver-specific 
OATP1B1 and 1B3 and losartan shares structural similarity (Yamashiro et al., 
2006 and Ishiguro et al., 2006).  Losartan, as a useful probe for CYP2C9 activity, 
is confounded by the fact that the drug is both passively and actively absorbed; 
therefore transporters may play a significant role in losartan disposition.  
Losartan has been used in various probe drug cocktails (Christensen et al., 2003; 
Ryu et al., 2007) and the ratio of E3174/losartan reflects CYP2C9 activity, 
however, the role of OATPs in losartan disposition is unknown. 
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 There is a large inter-individual variation for CYP2C9 activity and 
resulting in altered clinical response to therapeutics metabolized by this enzyme 
(Miners and Birkett, 1998).  This variation is most important for drugs possessing 
narrow therapeutic indices.  There have been 556 SNPs found in the introns and 
exons of the CYP2C9 sequence (Wang et al., 2009).  However, studies thus far 
did not reveal any association between CYP2C9 genotype and losartan AUC 
(Yasar et al., 2002; Lee et al., 2003).  It appears that CYP2C9 polymorphisms 
affect losartan pharmacokinetics from a minor to moderate extent; because at 
higher exposure, CYP3A4 plays a larger role in losartan metabolism (>25 µM) 
(Lee et al., 2003).  Pharmacokinetic interactions between fluvastatin and 
diclofenac (another CYP2C9 substrate) have been observed (Transon et al., 
1995); but fluvastatin does not alter the pharmacokinetics of losartan 
(Meadowcroft et al., 1999).  Fluconazole decreased the metabolism of losartan to 
E3174 (Kazierad et al., 1997; Kaukonen et al., 1998) by inhibition of both 
CYP3A4 and CYP2C9.  However, itraconazole, a CYP3A4-specific inhibitor, had 
no significant effect on losartan oxidation in vivo (Kazierad et al., 1997; 
Kaukonen et al., 1998). 
 
1.2.5: Fexofenadine 
 
Fexofenadine is a widely used, non-sedating second generation H1-
receptor antagonist.  While fexofenadine has been found to be a substrate for 
transporters, the antihistamine undergoes minimal metabolism in humans 
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(Lippert et al., 1995), thus making it a potential candidate for use as a probe drug 
for assessing transporter activity in human subjects. 
 
1.3: Fexofenadine Pharmacokinetics 
 
1.3.1: Fexofenadine in vivo  
 
Lippert et al. (1995) conducted a mass balance and metabolism study of 
fexofenadine where six healthy male subjects were given a single oral dose (60 
mg) of 14C-fexofenadine.  Recovery of radiolabeled fexofenadine was high, with 
80% of the dose found in the feces and approximately 12% found in the urine.  
The majority of the dose (> 85%) was recovered as unchanged fexofenadine, 
indicating that metabolism is an insignificant elimination route for fexofenadine 
and that fexofenadine is either poorly absorbed and/or is secreted back into the 
gastrointestinal tract. 
 
Stoltz et al. (1997) described the influence of food on the oral 
bioavailability of fexofenadine.  Administration of fexofenadine contained in a 
solid oral dosage form (as a capsule or tablet), in the presence of a high fat 
breakfast, resulted in decreases in fexofenadine AUC and Cmax, but not t1/2 or 
tmax.  Although the high fat breakfast was associated with decreases in extent of 
oral absorption, the magnitude of effect was much smaller than those for other 
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second generation antihistamines.  As a result, administration of fexofenadine on 
an empty stomach is not required. 
 
Russell et al. (1998) conducted a fexofenadine single- and multiple-dose 
pharmacokinetic and pharmacodynamic study in healthy male volunteers.  The 
purpose of this fexofenadine study was to establish a maximum tolerated dose, 
to characterize the single- and multiple-dose pharmacokinetics, and to 
characterize the pharmacodynamics of its antihistamine activity.  Fexofenadine 
was well tolerated at single-doses from 10 to 800 mg and at multiple-doses of 20 
to 690 mg for 28.5 days.  Mean Cmax for a single dose of fexofenadine dosed as 
an oral solution ranged from 46-6383 ng/mL and occurred one hour after dosing.  
The apparent elimination ranged from 7.7 to 14 hours after dosing, with oral 
clearance being approximately 30-55 L/hr for a single dose of fexofenadine.  For 
multiple dose studies of fexofenadine, steady state concentrations were reached 
5 days after twice daily dosing, with Cmax ranging from 58-4677 ng/mL.  Similar to 
that observed following single doses, the fexofenadine apparent elimination half-
life ranged from 8.8 to 12.9 hours.  Steady state mean oral clearance was 26-49 
L/hr and appeared to be independent of dose. 
 
1.3.2: Fexofenadine in vitro  
 
Transporters are involved in the pharmacokinetics of fexofenadine, thus, it 
is important characterize the roles of various human transporters involved in the 
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absorptive and distribution processes of this probe drug before being able to 
define its utility as a probe drug.  Cvetkovic et al. (1999) determined the uptake 
kinetics of fexofenadine by human OATP1A2 in transiently transfected HeLa 
cells.  The in vitro Km was determined to be 6 µM, with a Vmax of 58 pmol/mg 
protein/min (Cvetkovic et al., 1999).  They also demonstrated that P-glycoprotein 
was able to efflux fexofenadine using basolateral to apical transport in an LLC-
PK1 cell line overexpressing P-glycoprotein.  Fexofenadine is also transported in 
vitro by OATP1B3 with a Km of 108 µM (Shimizu et al., 2005), and one report 
suggested transport by OATP2B1 (Nozawa et al., 2004), however the signal 
appeared not to be statistically significant. 
 
1.4: Membrane Transporters Involved in Drug Absorption and Disposition 
 
After an orally administered drug undergoes dissolution within the 
gastrointestinal tract, it crosses the intestinal wall, reaches the liver via portal 
blood flow. Drug which is absorbed and escapes metabolism by the liver during 
this first pass through, will subsequently enter systemic circulation and distribute 
to the various tissues and organs throughout the body.  Drug elimination, is 
comprised of drug metabolism, most often primarily via the liver, and by excretion 
of parent drug and metabolites into bile or into urine.  Absorption, distribution, 
metabolism and excretion require that drugs pass through several biological 
membranes.  The extent of drug transport across these membranes is affected 
by the physicochemical properties of a drug, such as size, lipophilicity, charge, or 
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degree of ionization.  In addition, membrane transporters have a significant role 
in facilitating or preventing drug movement in and out of cells (Ho and Kim, 
2005).  These membrane transporters may be classified as uptake (influx into 
cell) or efflux (out of cell) transporters, which are typically located either on the 
basolateral or apical membrane in polarized cells.  Interplay of uptake and efflux 
transporters along with Phase I and II drug metabolizing enzymes may be 
required for drugs to cross the basolateral and apical membranes of cells 
(Giacomini et al., 2010). 
 
Transport of drugs across membranes plays an important role in intestinal 
absorption and first pass extraction of drugs.  Drug transport, in this context, 
involves both passive diffusion and carrier mediated transport [including P-
glycoprotein and the Organic anion transporting polypeptide (OATP) family of 
membrane transporters].  However, transport processes need to be better 
understood to appropriately interpret the in vitro pharmacokinetic transport data 
in comparison to actual drug absorption and disposition in vivo.  Another 
complexity lies in the overlapping substrate specificity of these membrane 
transporters, such that these substrates tend to be transported by more than one 
transporter or have drug-transporter interactions (Hagenbuch and Gui, 2008). 
 
Active and facilitative drug transporting proteins, like P-glycoprotein and 
the OATP family, play an important role in the absorption, distribution, 
metabolism, and excretion of drugs.  P-glycoprotein is highly expressed in the 
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intestine, liver, brain, and kidneys, and results in decreased absorption in the gut 
and prevents drugs from crossing the blood-brain barrier (Lin and Yamazaki et 
al., 2003).  Working in opposition to P-glycoprotein are the members of the OATP 
family of transporters, which act as uptake proteins and facilitate the intestinal 
absorption of drugs and xenobiotics, as well hepatic uptake and uptake across 
the blood brain barrier (Hagenbuch and Gui, 2008). 
 
1.4.1: Organic Anion Transporting Polypeptides and Uptake Transport 
 
Organic anion transporting polypeptides (OATP in humans, Oatp in other 
species) are members of the SLCO superfamily of membrane transporters 
(Hagenbuch and Meier, 2004).  They mediate the uptake of a wide number of 
substrates and have overlapping substrate specificity.  The most often studied 
and best-characterized OATPs are multi-specific and transport substrates in a 
sodium-independent manner.  There are eleven members of the OATP 
superfamily in humans, classified into six families based on amino acid identity 
(Hagenbuch and Meier, 2004).  OATPs are expressed at the mRNA level in 
many human tissues, including the liver, blood brain barrier, intestine, choroid 
plexus, lung, heart, kidney, placenta, and testis (Tamai et al., 2000).  Since our 
interest focuses on of the role of absorption and pre-systemic elimination of 
fexofenadine, we will focus only on the OATP family members expressed in 
enterocyte and hepatocyte. 
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The OATP1 family is the best characterized to date and the largest, with 
three subfamilies designated OATP1A, 1B, and 1C.  OATP1A2 is expressed in 
many tissues including the apical membrane of the small intestine, blood brain 
barrier, kidney, and cholangiocytes of the liver (Lee et al., 2005; Glaeser et al., 
2007).  OATP1B1 and 1B3 are present in the basolateral membrane of the 
hepatocyte and are thought to be liver specific (König et al., 2000a; König et al., 
2000b).  The OATP2 family has two members, including OATP2B1 which is 
expressed in the brain, liver, kidney, lung, and small intestine (Tamai et al., 2001; 
Kullak-Ublick et al., 2001; St-Pierre et al., 2002; Glaeser et al., 2007).  These four 
OATPs, OATP1A2, 1B1, 1B3, and 2B1, are the focus of this dissertation. 
 
1.4.2: Fexofenadine-Drug and Fexofenadine-Diet Interactions with OATP 
Family Members 
 
Fexofenadine has been shown in vitro to be a substrate for several 
members of the OATP family of transporters, specifically, OATP1A2 with a Km of 
6 µM (Cvetkovic et al., 1999), OATP1B3 with a Km of 108 µM (Shimizu et al., 
2005), and possibly OATP2B1 (Nozawa et al., 2004).  Although these three 
OATPs appear capable of transporting fexofenadine, their individual contributions 
to fexofenadine pharmacokinetics are not yet clear.  OATP1B1 has also been 
hypothesized to transport fexofenadine due to its structural similarity to 
OATP1B3; however, conflicting reports still exist as to whether OATP1B1 is 
capable of fexofenadine transport (Shimizu et al., 2005; Niemi et al., 2005; 
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Glaeser et al., 2007; Matsushima et al., 2008).  Glaeser et al. (2007) reported 
that OATP1A2 is the predominant uptake transporter of fexofenadine in the 
human enterocyte based on the results from both in vitro uptake experiments, as 
well as in vivo studies with human subjects. 
 
Some OATPs also transport angiotensin II receptor antagonists, more 
specifically, valsartan, olmesartan and telmisartan.  OATP1B1 and OATP1B3 
transport valsartan, with a Km of 1.4 µM and 18 µM respectively (Yamashiro et 
al., 2006).  Both OATP1B1 and OATP1B3 transport olmesartan in OATP1B1 and 
OATP1B3 expressing HEK293 cells with Km values of 12.8 µM and 44.2 µM, 
respectively (Yamada et al., 2007).  OATP1B3 and OATP2B1 are also capable of 
transporting telmisartan acyl glucuronide (Km 3.4 µM and 124 µM, respectively), 
however, OATP1B1 does not transport telmisartan aglucuronide (Ishiguro et al., 
2008).  Due to the structural similarity between these angiotensin II receptor 
antagonists, the CYP2C9 probe, losartan, may be a substrate of OATP1A2, 
OATP1B1, OATP1B3 and/or OATP2B1 and thus lead to drug-drug interactions 
with fexofenadine at these transporters. 
 
The discovery that grapefruit juice can inhibit fexofenadine transport was 
one of the earliest reports of a drug-food interaction at the level of transporters 
(Dresser et al., 2002).  The effect of grapefruit juice on drug metabolism was first 
reported with the calcium channel blockers felodipine and nifedipine (Bailey et 
al., 1991).  Subsequent studies showed that the target of grapefruit juice was not 
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the liver, but the small intestine, and grapefruit juice caused inhibition of CYP3A4 
activity in enterocytes (Lown et al., 1997).  Since more than 50% of all drugs are 
substrates of CYP3A4, the concomitant consumption of grapefruit juice with 
medications has led to elevated levels of many drugs, drug-drug interactions and 
even associated drug toxicities.  There is increasing evidence that grapefruit 
juice, as well as other juices also interact with membrane transporters, including 
the aforementioned P-glycoprotein as well as the OATP family of uptake 
transporters. 
 
Dresser et al. (2002) measured fexofenadine uptake via OATP1A2 in a 
transiently transfected HeLa cell line as well as in vivo using human subjects.  
OATP1A2-expressing cells or subjects were given a dose of fexofenadine with 
water, 25% strength grapefruit juice, normal strength grapefruit, orange, or apple 
juices or select grapefruit juice extracts.  The regular strength juices all inhibited 
fexofenadine uptake by OATP1A2 in a concentration dependent manner in vitro.  
These juices also reduced the plasma AUC and Cmax of fexofenadine 30-40% as 
compared to water alone in vivo.  The t1/2 and tmax of fexofenadine were not 
different among subject treatment groups.  Use of a 25% strength grapefruit juice 
produced a fexofenadine AUC and Cmax that was decreased 20% compared to 
that of water (Dresser et al., 2002). 
 
In another study, Dresser et al. (2005) examined the effect of volume of 
grapefruit juice on the bioavailability of fexofenadine.  Using both 300 mL of 
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grapefruit juice (a volume found in most single serve bottles of grapefruit juice) 
and 1200 mL of grapefruit juice in combination with an oral dose of fexofenadine, 
grapefruit juice co-administration decreased the bioavailability of oral 
fexofenadine significantly.  The 300 mL volume of grapefruit juice inhibited 
fexofenadine adequately to be clinically relevant and was hypothesized to be due 
to direct inhibition of OATP1A2 (Dresser et al. 2005). 
 
Since inhibition of fexofenadine uptake due to grapefruit juice ingestion 
represented direct inhibition of OATP1A2, Glaeser et al. (2007) assessed the 
expression of various human transporters in the intestine, as well as the 
subcellular localization of OATP1A2, and the effect of grapefruit juice 
consumption on OATP1A2 expression.  Human duodenal biopsy samples were 
utilized to measure expression of various uptake and efflux transporters in vivo.  
Uptake transporters found at the mRNA level in the small intestine of subjects 
sampled included OATP1B1, OATP1B3, OATP1A2, and OATP2B1; however, at 
the protein level, only OATP1A2 and 2B1 were detected.  In vitro experiments 
using transiently transfected cell lines showed only OATP1A2 (Cvetkovic et al., 
1999; Glaeser et al., 2007) and OATP1B3 (Shimizu et al., 2005) capable of 
fexofenadine transport.  Immunohistochemical staining of human duodenal 
biopsies showed co-localization of OATP1A2 and P-glycoprotein to the apical 
brush border of enterocytes (Glaeser et al., 2007).  Consumption of grapefruit 
juice by human subjects two hours before or concomitantly with fexofenadine 
administration was associated with reduced oral fexofenadine AUC and Cmax, 
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though intestinal expression of OATP1A2 and P-glycoprotein remained 
unchanged.  In conclusion, Glaeser et al. (2007) hypothesized that OATP1A2 is 
the key intestinal uptake transporter for fexofenadine and its inhibition by 
grapefruit juce is responsible for the interaction. 
 
Bailey et al. (2007) further illustrated that flavonoids found in grapefruit 
juice (naringin) and orange juice (hesperidin) are involved in the direct inhibition 
of OATP1A2 in vitro and decrease the bioavailability of fexofenadine in vivo.  
Naringin had an IC50 that was several hundred-fold lower than that normally 
found in grapefruit juice (3.6 μM) and caused complete inhibition of in vitro 
OATP1A2-mediated fexofenadine uptake.  Hesperidin also had a low IC50 
compared with the typical concentration in orange juice but produced only 60% 
maximum inhibition.  From these studies, naringin and hesperidin seemed to be 
the main components in their respective juices regarding in vitro inhibition of 
OATP1A2-mediated fexofenadine uptake. 
 
Qiang et al. (2009) reported a fexofenadine-drug interaction in rats 
involving fluvastatin.  Dosing rats orally with the combination of fexofenadine and 
fluvastatin decreased fexofenadine AUC by 17-50%.  However the concurrent 
use of fluvastatin did not affect the intravenous pharmacokinetics of fexofenadine 
suggesting that the interaction occurs at the level of the gastrointestinal tract.  
They hypothesize that the interaction seen between fexofenadine and fluvastatin 
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may be occurring at an OATP contained within the gastrointestinal tract, 
sinceboth drugs are substrates of multiple OATPs. 
 
In order to test the Kansas Cocktail in healthy volunteers, initial validation 
of the probe cocktail was required.  Of primary importance was testing for 
pharmacokinetic interactions between the various probe drugs.  To assess 
whether the probe drugs were interacting, changes in parent/metabolite ratios or 
changes in AUC were examined.  While none of the CYP probes interacted with 
each other, there was a significant interaction between fexofenadine and one or 
more of the other probe cocktail components.   
 
When fexofenadine AUC was compared in 14 subjects after administration 
of fexofenadine alone versus co-administration of fexofenadine with the other 
four probe compounds as part of the 5-drug cocktail, half of the subjects showed 
a 50% or greater decrease in the AUC for fexofenadine in the presence of the 
cocktail (Figure 1.2).  Based on this observation, we hypothesized that an 
enterocyte expressed OATP that was involved in the absorption of fexofenadine 
was inhibited by one or several CYP probe drugs in the cocktail, resulting in this 
decrease in AUC.
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Figure 1.2: 
 
 
 
 
 
 
 
 
 
 
 
 
A Unique Drug-Fexofenadine Interaction Seen With The Kansas Cocktail.  A 
probe drug-fexofenadine interaction was seen in human subjects that decreased 
fexofenadine AUC by 40-60% in greater than half the subjects (A), as well as 
decreased Cmax (B), indicating that this interaction was occurring pre-
systemically.  Fexofenadine half-life and clearance were not affected.
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1.4.3: OATP1A2 Polymorphisms in Humans 
 
The broad substrate specificity of OATP1A2 includes many drugs used 
clinically and the expression of OATP1A2 is found in organs responsible for drug 
distribution.  Therefore, genetic variations in OATP1A2 (gene SLCO1A2) may 
have significant implications on the disposition of such drugs.  Genetic variants 
may exhibit altered kinetics for transport of a substrate, or may also differ in the 
occurrence and magnitude of drug-drug or drug-diet interactions. 
 
Lee et al. (2005) identified 6 non-synonymous polymorphisms within the 
coding region of SLCO1A2 (Ile13Thr, Asn128Tyr, Asn135Ile, Glu172Asp, 
Ala187Thr, and Thr668Ser).  In vitro functional studies revealed that the 
Glu172Asp and Asn135Ile variants had reduced uptake capacity of model 
substrate estrone-3-sulfate and two opioid receptor antagonists.  Other variants 
had altered transport activity that was substrate specific.  Further kinetic analysis 
of transport data indicated that mutations at codons 128, 135, 172, 187, and 668 
would have functional consequences (Lee et al., 2005). 
 
Badagnani et al. (2006) identified seven novel OATP1A2 variants from 
270 ethnically diverse samples.  Four of the seven variants were found to be 
protein altering and subsequently had altered transport of estrone-3-sulfate 
and/or methotrexate.  Single nucleotide polymorphism Ile13Thr increased model 
substrate transport creating a hyperfunctional OATP1A2, variant Arg168Cys 
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created a hypofunctional OATP1A2, and the Glu172Asp variant created an 
OATP1A2 with reduced maximal transport capacities. 
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1.5: Specific Aims of This Dissertation 
 
Membrane transporters are key modulators, altering disposition of drugs 
and other chemicals, via absorption, distribution, metabolism, and elimination 
from the body.  While the importance of membrane transporters is well 
understood, better-characterized tools are needed to support continuing 
investigations of their specific functions both in vitro and in vivo.  To better study 
and understand transporter function in vivo a safe and well-characterized probe 
drug is required.  Fexofenadine is a promising probe for the study of transporter 
functions in humans because the drug is incredibly safe, is essentially not 
metabolized, and a substrate for transporters.  Use of fexofenadine as a probe, 
however, requires a clear understanding of the roles of the different transporters 
involved in its disposition.  The long-term goal of this dissertation is to define the 
utility of fexofenadine as a probe for characterizing the activity of uptake and 
efflux transporters in humans.  By doing so, we can identify sources of within and 
between-subject variability (e.g., transport polymorphisms), and to predict drug-
drug interactions.  Ultimately, this research will contribute the optimization of drug 
therapy. 
 
Several members of the organic anion transporting polypeptide (OATP) 
family of transporters are thought to contribute to fexofenadine pharmacokinetics; 
however their individual contributions have not been well defined.  Since there 
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are conflicting reports as to the contribution of specific transporters on the 
pharmacokinetics of fexofenadine, the objective of this dissertation was to 
identify the dominant transporter(s) involved in fexofenadine pharmacokinetics 
and to further validate the utility of fexofenadine as a probe for transporter activity 
in humans.  The previously unreported fexofenadine-drug interaction in a clinical 
study provides an additional approach for defining the specific transporter(s) of 
fexofenadine uptake and efflux. 
 
To understand the role(s) of transporters in drug-drug interactions, 
defining the dominant transporter(s) of fexofenadine and their relative 
contributions will illustrate best how human transporters function and how this 
function can be modulated.  The central hypothesis of this study is that drug-drug 
interactions at a transporter facilitating uptake of fexofenadine decreases 
fexofenadine uptake in vivo, and thereby alters fexofenadine pharmacokinetics.  
We tested this hypothesis with the following specific aims: 
 
1.5.1: Specific Aim 1 
 
Development and validation of an LC-MS/MS method for the 
measurement of fexofenadine.  The method developed was specific for 
fexofenadine, rapid, and with sufficient sensitivity for the studies proposed.  
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Based on previous reports using radiolabeled fexofenadine quantities of 
fexofenadine taken up by transporters are in the picogram range. 
 
1.5.2: Specific Aim 2 
 
First, it was important to define and characterize the kinetics of 
fexofenadine with human OATPs expressed in the enterocyte and the 
hepatocyte.  The transporters studied were OATP1A2, 1B1, 1B3, and 2B1.  
Using transiently transfected HEK293 cells expressing OATP1A2, as well as 
stable CHO cell lines for OATP1B1, 1B3, and 2B1, fexofenadine kinetics (Km) 
were measured.  The analytical method developed in Specific Aim 1 was used to 
measure fexofenadine uptake in these systems.  The studies proposed test the 
current hypothesis that OATP1A2 is capable of fexofenadine transporter in the 
human enterocyte and hepatocyte. 
 
1.5.3: Specific Aim 3 
 
Identification of probe drug(s) interacting with fexofenadine at previously 
described transporter(s) in vitro allowed the determination of fexofenadine-drug 
interaction seen clinically.  Based on observations in a previous clinical study, a 
decrease in fexofenadine Cmax and AUC occured when fexofenadine was dosed 
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as part of a 5-drug cocktail (losartan, buspirone, fexofenadine, caffeine, and 
dextromethorphan) as compared to a single dose of fexofenadine.  
Characterization of the interaction of probe drugs with fexofenadine at a specific 
transporter(s) provides further support for the identity of the dominant uptake 
transporter controlling fexofenadine pharmacokinetics.  To examine drug-drug 
interactions with membrane transporters, we used the same transiently 
transfected HEK293 cells and stably transfected CHO cell lines described in 
Specific Aim 2.  Fexofenadine transport was measured by LC-MS/MS and the 
effects of the other four probe drugs were determined. 
 
1.5.4: Specific Aim 4 
 
Exploration of the effect of OATP1A2 genotypes on fexofenadine transport 
kinetics and fexofenadine-probe drug interactions was also studied.  Using three 
known human single nucleotide polymorphisms (SNPs), we used site-directed 
mutagenesis to create three OATP1A2-mutant transporters.  After verification of 
their sequences, we transiently transfected HEK293 cells with each of the 
mutated transporters and determined the effects of these mutations on the 
transport of fexofenadine as well as the effects of the other probe drugs on 
fexofenadine transport. 
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Chapter 2 
Experimental Materials and Methods 
 
2.1: Materials 
 
 [3H] Estrone-3-sulfate (E3S; 54.26 Ci/mmol) and [3H] estradiol-17β-glucuronide 
(E17-βG; 41.8 Ci/mmol) were purchased from PerkinElmer Life and Analytical Sciences 
(Waltham, MA).  Sodium butyrate was purchased from Sigma-Aldrich (St. Louis, MO).  
Fexofenadine hydrochloride was obtained from Toronto Research Chemicals (Toronto, 
Ontario, Canada), buspirone hydrochloride, caffeine, dextromethorphan hydrobromide, 
losartan potassium, and cetirizine hydrochloride (internal standard, IS) were obtained 
from Sigma Aldrich (St. Louis, MO, USA).  Ammonium formate, methanol, acetonitrile, 
and formic acid, all of HPLC or Optima grade, were from Fisher Scientific (Fair Lawn, 
NJ, USA).  Purified water was from a Millipore Q Water System (Millipore, Bedford, MA, 
USA).  All other chemicals were analytical grade and purchased from Sigma-Aldrich or 
Fisher Scientific. 
 
 Human embryonic kidney (HEK293) cells, Eagle's minimum essential medium, 
and Dulbecco's modified Eagle's medium (high glucose) were from American Type 
Culture Collection (Manassas, VA).  Dulbecco's modified Eagle's medium (low glucose) 
was purchased from Caisson Laboratories (North Logan, UT).  Fetal bovine serum 
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(FBS) was obtained from HyClone (Logan, UT). Sulfo-NHS-SS-biotin, NeutrAvidin 
agarose beads and the BCA protein assay kit were from Thermo Fisher Scientific 
(Rockford, IL).  All other cell culture materials were purchased from Sigma-Aldrich or 
Invitrogen (Carlsbad, CA). 
 
2.2: LC-MS/MS Sample Preparation 
 
 Fexofenadine and cetirizine (IS) stock solutions (1 mg/mL) were individually 
prepared in methanol.  Busprione, caffeine, dextromethorphan, and losartan stock 
solutions (1 mg/mL) were individually prepared in water.  The internal standard was 
diluted to 100 ng/mL (working concentration) by diluting the stock solution with and a 
diluent composed of 7.5 mM ammonium formate, pH 5, methanol, acetonitrile (50:25:25, 
v/v/v).  This same diluent was used for all dilutions and for sample reconstitution. 
 
 HEK293 cell culture lysates were spiked with 25 or 50 µL of fexofenadine 
working solutions to obtain final fexofenadine concentrations of 0, 1, 2, 5, 10, 50, 100, 
and 500 ng/mL fexofenadine, containing the IS at a concentration of 10 ng/mL.  Quality 
control (QC) samples were prepared independently on separate days at concentrations 
of 3 (low), 75 (medium), 400 and 500 (high) ng/mL fexofenadine.  Similar working 
solutions were also made for the other components of the probe drug cocktail 
(buspirone, caffeine, dextromethorphan, and losartan).  HEK293 cell culture lysates 
were spiked with probe drugs to obtain final concentrations of of 0-500 ng/mL probe 
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drug, with the IS at a concentration of 10 ng/mL.  QC samples were prepared 
independently for each probe drug at concentrations between 3 and 500 ng/mL. 
 For in vitro studies of fexofenadine transport, the matrix was a mammalian cell 
lysate derived from HEK293 cells transiently transfected with the uptake transporter 
OATP1A2.  Confluent monolayers of HEK293 cells containing OATP1A2 in 24-well 
plates were washed with uptake buffer (142 mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.2 
mM MgSO4, 1.5 mM CaCl2, 5 mM glucose and 12.5 mM Hepes, and was adjusted to pH 
7.4 with Tris base) three times and then frozen overnight.  Cells then were thawed and 
150 µL of diluent containing the desired concentration of fexofenadine and the internal 
standard (final concentration 10 ng/mL cetirizine) was added and cells were lysed at 
room temperature for 20 minutes on a rocker platform.  This mixture was centrifuged at 
20,000 rpm for 5 minutes to pellet precipitated protein.  Lysates were then transferred to 
a round bottom 96-well plate and 10 µL was injected for analysis. 
 
2.3: LC-MS/MS Conditions 
 Chromatography was performed using a Luna C18 column (5 µm, 50 x 2 mm), 
fitted with a C18 4 x 2 mm guard column (Phenomenex, Torrance, CA, USA) at 40 ºC.  
The aqueous mobile phase (Solvent A) was 7.5 mM ammonium formate, pH 5, and the 
organic mobile phase (Solvent B) was acetonitrile and methanol (50:50, v/v).  Total flow 
rate was 0.5 mL/min.  The gradient used allows the quantification not only of 
fexofenadine but also of the other probe drugs employed, namely buspirone, caffeine, 
dextromethorphan, and losartan.  Elution was performed with a linear gradient from 5% 
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to 90% Solvent B from 0-2 minutes, elution with 90% B for 0.5 minutes, and then a 
linear decrease to 5% B over 0.75 minutes.  Total run time was 5 minutes. 
 
 Mass spectrometry was performed using a Waters Quattro Premier mass 
spectrometer (Waters Corporation, Milford, MA, USA) in the positive ion electrospray 
mode.  Source temperature was 120 ºC, with a desolvation temperature of 350 ºC.  
Cone gas flow was set at 60 L/hr and a desolvation gas flow of 650 L/hr.  The mass 
spectrometer was operated in the MRM mode with a dwell time of 0.050 seconds per 
MRM channel.  Fexofenadine, probe drugs, or internal standard (cetirizine) at a 
concentration of 100 µg/mL in methanol was infused directly into the source of the mass 
spectrometer to determine characteristic product ions of the analytes and IS (Table 2.1).  
Data acquisition was performed with MassLynx (Version 4.12) and quantitation of 
results with QuanLynx software.
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Table 2.1: Characteristic Product Ions of The Kansas Cocktail and Internal 
Standard. 
 
Analyte Precursor 
Ion (m/z) 
Product 
Ion (m/z) 
Cone (V) Collision (V) 
Fexofenadine 502.17 466.2 44 26 
Buspirone 386.32 122.3 50 30 
Caffeine 195.26 138.2 35 30 
Dextromethorphan 271.28 121.22 40 18 
Losartan 422.98 207.2 26 24 
Cetirizine (IS) 389.02 201.1 30 20 
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2.4: Bioanalytical Method Validation 
 
 Standards for calibration curves were prepared by spiking aliquots of diluent or 
cell culture lysate with 10 ng/mL cetirizine (IS) and seven non-zero analyte 
concentrations, covering a range of 1-500 ng/mL fexofenadine.  The calibration curves 
for standards in diluents and in cell lysates, were generated on consecutive days from 
samples injected in duplicate using the analyte to IS peak area ratios by weighted (1/x) 
least squares linear regression.  Acceptance criteria for calibration curves were a 
correlation coefficient (r2) of 0.99 or greater and standard concentrations determined 
within 15% of the actual value, the exception being the LLOQ which must be within 20% 
of the actual value.  The precision and accuracy of the method was determined by 
analyzing three sets of QC samples (low, medium, high), with each batch containing five 
replicates of each concentration level, analyzed on consecutive days.  Precision of the 
method was calculated by determining the coefficient of variation (CV).  The acceptable 
criteria for intra- and inter-day precision were <15% for all non-LLOQ samples and 
<20% for the LLOQ.  Accuracy of the method was considered acceptable if measured 
values were between 85-115% of the actual value, or 80-120% for the LLOQ. 
 
 Extraction recovery of the analyte (fexofenadine) was determined by comparing 
the raw peak area of fexofenadine isolated from spiked cell culture matrix to the peak 
area of the analyte at the same concentration in diluent.  Similar methodology was used 
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to validate the other 4 components of the probe drug cocktail (buspirone, caffeine, 
dextromethorphan, and losartan) and met the same criteria for method validation. 
 
2.5: Cell Culture  
 
HEK293 cells were grown in Dulbecco’s modified Eagle’s medium containing 4.5 
g/L D-glucose, 2 mM L-glutamine, 25 mM Hepes buffer, and 110 mg/L sodium pyruvate, 
supplemented with 10% FBS, 100 U/mL penicillin, and 100 μg/mL streptomycin.  CHO 
cells stably expressing OATP2B1 or the empty vector were grown in F-12 Nutrient 
Mixture containing 10% FBS, 2 mM L-glutamine, 100 U/mL penicillin, 100 μg/mL 
streptomycin, and 400 µg/mL Hygromycin B.  CHO cells stably expressing OATP1B1, 
OATP1B3, or wild-type (WT) were grown in Dulbecco's modified Eagle medium, 
containing 1 g/L D-glucose, 2 mM L-glutamine, 25 mM Hepes buffer and 110 mg/L 
sodium pyruvate, supplemented with 10% FBS, 50 μg/mL L-proline, 100 U/mL penicillin 
and 100 μg/mL streptomycin.  All cells were maintained in a humidified environment at 
37°C and 5% CO2. 
 
 
 
 
34 
 
2.6: OATP Expression 
 
HEK293 cells (200,000 cells per well) were seeded on 24-well plates pre-treated 
with poly-D-lysine, and were transfected with pExpress-1 (Express Genomics, Inc., 
Frederick, MD) containing OATP1A2, or the empty vector, and Fugene HD (Roche 
Diagnostics, Indianapolis, IN) 48 hours prior to uptake experiments.  CHO cells stably 
transfected with human OATP2B1 have been previously described (Pacyniak et al., 
2010).  CHO cells stably expressing OATP2B1 or the empty vector (pCDNA5/FRT) 
were seeded on 24-well plates (100,000 cells per well) 48 hours prior to uptake 
experiments; OATP2B1 expression in this cell line did not require sodium butyrate 
induction.  OATP1A2 mutant constructs were also transiently expressed in HEK293 
cells. Cells were seeded in 24-well tissue culture plates (200,000 cells per well), pre-
coated with poly-D-lysine.  At 90% confluence, cells were transfected with wild-type or 
mutant OATP1A2 constructs (Badagnani et al., 2006) or the empty plasmid using 
FuGENE-HD transfection reagent (Roche, Basel, Switzerland), following manufacturer’s 
instructions.  All experiments were performed forty-eight hours after transfection. CHO 
cells stably transfected with human OATP1B1 and OATP1B3 have been previously 
described (Gui et al., 2008).  CHO cells stably expressing OATP1B1 or OATP1B3 or 
wild-type cells were plated at 40,000 cells per well on 24-well plates and 48 hours later 
medium was replaced with medium containing 5 mM sodium butyrate to induce 
nonspecific gene expression.  After an additional 24 hours in culture, the cells were 
ready for uptake experiments. 
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2.7: Transport Experiments 
 
For experiments with OATP1A2, HEK293 uptake buffer contained 142 mM NaCl, 
5 mM KCl, 1 mM KH2PO4, 1.2 mM MgSO4, 1.5 mM CaCl2, 5 mM glucose and 12.5 mM 
Hepes, and was adjusted to pH 7.4 with Tris base.  For experiments with OATP1B1, 
1B3, and 2B1, CHO uptake buffer contained 116.4 mM NaCl, 5.3 mM KCl, 1 mM 
NaH2PO4, 0.8 mM MgSO4, 5.5 mM D-glucose and 20 mM HEPES, and was adjusted to 
pH 7.4 with Tris base.  For experiments using the OATP1A2 mutants, HEK293 buffer 
was used. 
 
Cells in 24-well plates were washed with uptake buffer pre-warmed to 37°C and 
then incubated on a 37°C warming block with uptake buffer containing substrates and/or 
inhibitors for the indicated time periods.  Uptake was terminated by removing the uptake 
solution and washing the cells with 4°C uptake buffer.  To measure uptake of 
radiolabeled substrates, cells were lysed with 1% Triton X-100 in PBS, and the 
radioactivity was quantified with liquid scintillation counting.  Protein concentrations 
were determined with a BCA assay kit (Thermo Fisher Scientific, Rockford, IL) and 
uptakes were normalized based on protein concentration. 
 
Unlabeled probe drugs were measured using high performance liquid 
chromatography-tandem mass spectrometry (LC-MS/MS).  Cells were lysed in a mobile 
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phase of 50:50 (v/v) 7.5 mM ammonium formate, pH 5 and 50:50 (v/v) acetonitrile and 
methanol containing 10 ng/mL cetirizine as an internal standard and prepared for 
analysis as described previously (Flynn et al., 2011).  Probe drugs were separated by 
reverse phase chromatography using a Phenomenex C18 column (Phenomenex Inc., 
Torrance, CA, 50 x 2.1mm, 5 µm) at 40 °C.  Mobile phase consisted of 7.5 mM 
ammonium formate, pH 5 and 50:50 (v/v) acetonitrile and methanol.  The flow rate was 
0.5 mL per minute with gradient elution, allowing a run time of 5 minutes.  Drugs were 
detected and quantified in electrospray positive ion mode with a Waters Quattro Premier 
(Waters Corporation, Milford, MA).  The transitions monitored were 502.17 > 466.2 for 
fexofenadine, 386.32 > 122.3 for buspirone, 195.26 > 138.2 for caffeine, 272.34 > 171 
for dextromethorphan, 422.98 > 207.2 for losartan, and 389.1 > 201.1 for cetirizine 
(internal standard).  QuanLynx software (Waters Corporation, Milford, MA) was utilized 
to quantify mass spectrometry data. 
 
Protein concentrations were determined with a BCA assay kit (Thermo Fisher 
Scientific, Waltham, MA), and uptake was normalized to protein.  Net OATP-mediated 
uptake was defined as the uptake by OATP-expressing cells minus the uptake by the 
control cell line (HEK293 cells transiently expressing the empty vector p-Express 1 for 
transiently expressed OATP1A2 and its mutants, CHO cells stably expressing the 
empty vector pCDNA5/FRT for OATP2B1, and wild-type CHO cells for OATP1B1 and 
OATP1B3). 
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2.8: Surface Biotinylation and Western Blot Analysis 
 
Cell surface expression was measured by incubating cells with 1 mg/ml sulfo-
NHS-SS- biotin in PBS for 1 hour at 4°C.  After stopping the reaction with 100 mM 
glycine in phosphate buffered saline, cells were lysed for 10 minutes on ice, in buffer 
containing 10 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1% Triton X-
100 and protease inhibitors.  This lysate was centrifuged at 10,000 x g for 2 minutes.  
Cell supernatant was added to 70 µL neutravadin agarose beads and incubated for 1 
hour at room temperature.  Beads were washed three times for 5 minutes with lysis 
buffer, then the biotinylated proteins were eluted by incubating with 2x Laemmli buffer 
containing 5% 2-mercaptoethanol for 30 minutes.  Protein was run on a 6% SDS-PAGE 
gel and transferred to nitrocellulose membrane.  Western blots were probed with a 
monoclonal OATP1A2 antibody from Santa Cruz Biotechnology (Valencia, CA), 
following the manufacturer’s recommendations. 
 
2.9: Data and Statistical Analysis 
 
Transporter-mediated net uptake was obtained by subtracting the uptake in 
control cells from that in OATP-expressing cells.  Inhibition of transporter-mediated 
uptake was calculated based on the difference between net uptake of a substrate in the 
absence of inhibitor and net uptake in the presence of inhibitor.  Data were fit to 
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Michaelis-Menten kinetics using GraphPad Prism 5 (La Jolla, CA).  Statistical analysis 
of differences between treatments was performed using SigmaPlot 11.0 utilizing a one-
way analysis of variance (one-way ANOVA) and Bonferoni post-hoc test (SyStat 
Software Inc., San Jose, CA).  P-values less than 0.05 (p<0.05) are considered 
significant and were denoted by an asterisk.
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Chapter 3 
Quantification of the Transporter Substrate Fexofenadine in Cell Lysates by  
LC-MS/MS 
 
3.1: Abstract 
 
 Drug-drug interactions at transporters present a significant and under-
investigated clinical problem.  Investigations of specific transporter functions and 
screening for potential drug-drug interactions, both in vitro and especially in vivo, will 
require validated experimental probes.  Fexofenadine, an approved, well-tolerated drug, 
is a promising probe for studies of membrane transporter function.  Although 
fexofenadine pharmacokinetics are known to be controlled by transporters, the 
contributions of individual transporters have not been defined.  We have developed a 
rapid, specific, and sensitive analytical method for quantitation of fexofenadine to 
support this work.  This LC-MS/MS method quantifies fexofenadine in cell lysates from 
in vitro studies using cetirizine as the internal standard.  Cell lysates were prepared for 
analysis by acetonitrile precipitation.  Analytes were then separated by gradient reverse-
phase chromatography and analyzed by tandem mass spectrometry using the m/z  
______________________________________________________________________ 
Reprinted with permission of John Wiley and Sons.  All rights reserved.  Rapid 
Commun. Mass Spectrom. 2011, 25, 2361–2366. 
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502.17/466.2 transition for fexofenadine and m/z 389.02/201.1 for cetirizine.  The 
method exhibited a linear dynamic range of 1–500 ng/mL for fexofenadine in cell 
lysates.  The lower limit of quantification was 1 ng/mL with a relative standard deviation 
of less than 5%.  Intra- and inter-day precision and accuracy were within the limits 
presented in the FDA guidelines for bioanalysis.  We also will validate this method to 
support not only the quantification of fexofenadine, but also other probe drugs for drug-
drug interaction studies.  This method for quantification will facilitate the use of 
fexofenadine as a probe drug for characterization of transporter activity. 
 
3.2: Introduction 
 
 Fexofenadine, a non-sedating H1-receptor antagonist, is a substrate of the 
uptake transporter organic anion transporting polypeptide 1A2 (OATP1A2) and the 
efflux transporter, P-glycoprotein (P-gp) (Cvetkovic et al., 1999; Glaeser et al., 2007).  
Additional reports have suggested that OATP1B1, OATP1B3, and OATP2B1 might also 
transport fexofenadine (Kim 2003; Shimizu et al., 2005).  Ninety-five percent of 
fexofenadine is excreted unchanged, with only 1% metabolized prior to excretion 
(Lippert et al., 2005), thus fexofenadine pharmacokinetics are controlled by 
transporters, rather than by metabolism.  The pharmacokinetics of fexofenadine 
suggests that it might be a useful probe drug for functional studies of both the OATP 
family of transporters and P-glycoprotein (Dresser et al.; 2002).  However, the precise 
contributions of individual transporters to fexofenadine pharmacokinetics are still 
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unknown (Hamman et al., 2001; Dresser et al., 2002; Wang et al., 2002).  This will 
require careful characterization of fexofenadine transport in model systems to define the 
relative roles of these various transporters.  Both in vitro studies to identify transporters 
with high affinity for fexofenadine, and in vivo studies to characterize the role of 
fexofenadine as a selective probe for certain transporter activity, will require a 
bioanalytical method that is accurate, rapid, sensitive, and selective for this probe drug. 
 
 Previous methods for quantification of fexofenadine have been described based 
on HPLC using fluorescence detection (Coutant et al., 1991; Uno et al., 2004).  Those 
methods, however, required relatively long analysis times and provide less sensitivity 
and specificity than required for our studies.  Due to these issues, high selectivity and 
sensitivity LC-MS/MS methods were developed for the quantification of fexofenadine.  
However, these methods had relatively long run times (>10 minutes) and were validated 
for the quantification of fexofenadine in plasma or urine samples (Hofmann et al., 2002; 
Fu et al., 2004).  To meet the need for the bioanalytical support for cell-based 
transporter assays, we have developed and validated an LC-MS/MS method for the 
identification and quantification of this drug in cell culture lysates using cetirizine as the 
internal standard.  This method will be applied to the analysis of fexofenadine in 
mammalian cell lysates from in vitro transporter studies, and will be developed further to 
measure other probe drugs to support drug-drug interaction studies in these model 
systems. 
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3.3: Results 
 
3.3.1: Mass Spectrometry. 
 
 Figure 3.1.1 and 3.1.2 shows the mass spectra obtained for fexofenadine and the 
internal standard cetirizine.  Fragmentation of fexofenadine shows its characteristic 
product ions at m/z of 131.1, 171.2, 189.0, 233.9, 262.3, and 466.2.  The two most 
abundant ions are 466.2 and 171.2 (m/z). For cetirizine a characteristic product ion at 
m/z 200.9 was observed.  The most sensitive transitions were 502.17/466.2 for 
fexofenadine and 389.09/201.1 for the internal standard cetirizine. 
 
3.3.2: Chromatography. 
 
 Chromatographic conditions were optimized by testing aqueous mobile phases 
that varied in pH from 3 to 8, and by using methanol, acetonitrile, or a 50/50 (v/v) 
methanol-acetonitrile mixture as the organic phase.  Based on sensitivity, peak shape 
for the analyte and internal standard, and on overall run time, we found that a gradient 
of ammonium formate (7.5 mM, pH 5) and acetonitrile-methanol (50:50, v/v) achieved 
the best chromatographic results.  This mobile phase allowed elution of fexofenadine at 
2.48 minutes and the internal standard at 2.66 minutes with a total run time of less than 
five minutes.  Although ideal for analysis of fexofenadine alone, we also anticipate the 
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need to measure additional analytes as we investigate drug-drug interactions at 
membrane transporters.  To support this future need, we modified the method to include 
other probe drugs of interest.  Use of the same gradient we developed for fexofenadine 
alone also yielded acceptable retention of the relatively polar probe drug caffeine and 
the elution of fexofenadine, three other less polar probe drugs (buspirone, 
dextromethorphan, losartan), and the internal standard within 5 minutes (data not 
shown). 
3.3.3: Selectivity. 
 
 Method selectivity was examined by analyzing blank cell culture matrix samples 
and matrix spiked only with IS.  As seen in Figure 3.2.1, there is no endogenous 
compound interference at the retention times of the analyte or internal standard.  
Similarly, the internal standard does not show any crossover in the MRM of the analyte 
in Figure 3.2.2.  The MRM chromatogram in Figure 3.2.3 illustrates the result from a 
sample spiked with 1 ng/mL fexofenadine, demonstrating the sensitivity of the method. 
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Figure 3.1.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum Obtained For Fexofenadine.  A product spectrum for fexofenadine 
was generated by direct infusion into the ESI probe with the most sensitive transition 
being 502.17/466.2 m/z.
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Figure 3.1.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mass Spectrum Obtained For Cetirizine. A product spectrum for cetirizine was 
generated by direct infusion into the ESI probe with the most sensitive transition being 
389.09/201.1 m/z. 
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Figure 3.2.1: 
 
 
 
 
 
 
 
 
 
 
 
 
MRM Chromatogram From Blank Cell Lysate.  Aliquots of HEK293 cell lysates were 
spiked, prepared by lysis with mobile phase, analyzed by LC-MS/MS, and quantified as 
described in Materials and Methods.  This chromatogram is from analysis of a sample 
prepared from blank cell lysate only.
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Figure 3.2.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
MRM Chromatogram of Cetirizine (Internal Standard).  Aliquots of HEK293 cell 
lysates were spiked with cetirizine, prepared by lysis with mobile phase, analyzed by 
LC-MS/MS, and quantified as described in Materials and Methods.  This chromatogram 
is from analysis of a sample that contained 10 ng/mL cetirizine only. 
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Figure 3.2.3: 
 
 
 
 
 
 
 
 
 
 
 
 
MRM Chromatogram of Fexofenadine and Cetirizine.  Aliquots of HEK293 cell 
lysates were spiked with cetirizine and fexofenadine, prepared by lysis with mobile 
phase, analyzed by LC-MS/MS, and quantified as described in Materials and Methods.  
This chromatogram is from analysis of a sample containing both 10 ng/mL internal 
standard and fexofenadine at the LLOQ, 1 ng/mL. 
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3.3.4: Linearity. 
 
 The seven-point calibration curve for fexofenadine extracted from HEK293 cell 
lysates was linear over the selected concentration range of 1-500 ng/mL fexofenadine.  
The best linear fit and linear regression were obtained with a 1/x weighing factor.  Figure 
3.3 illustrates a representative standard calibration curve for fexofenadine in cell lysates, 
with an r2 of 0.99.  Table 3.1 summarizes the calibration curve results, illustrating our 
ability to both precisely and accurately measure fexofenadine in mobile phase.  
Fexofenadine quantitation at 1 ng/mL was accomplished with a precision (CV) of 2.6% 
and a mean accuracy of 106.5%, well within the limits for defining the LLOQ.  Similarly, 
the precision and accuracy of each concentration of fexofenadine in the calibration curve 
met the FDA criteria for bioanalytical method validation (FDA, 2001).  The inter-day 
coefficient of variation (CV) for the lowest QC standard (3 ng/mL) in cell lysate is 9.5% 
and the between batch accuracy was 97.4% (Table 3.2).  Within the batches, the low QC 
standard had a CV of 8.5% and the accuracy was 91.9%.  For the middle and upper 
quantification levels (ranging from 75-500 ng/mL), the precision (CV) ranged from 2.5-
6.2% and the accuracy from 90.1-97.0% within batch (Table 3.2).  Between batches, the 
precision ranged from 3.4-4.9% and the accuracy from 97.4-103.6% in HEK293 cell 
lysate. 
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Figure 3.3: 
 
 
 
 
 
 
 
 
Calibration Curve for Fexofenadine in HEK293 Cell Lysate.  Aliquots of HEK293 cell 
lysates were spiked with the from 0-500 ng/mL fexofenadine and with 10 ng/mL of the 
internal standard, cetirizine.  Samples were prepared by prepared by lysis with mobile 
phase, analyzed by LC-MS/MS, and quantified as described in Materials and Methods. 
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Table 3.1: Precision and Accuracy Data for Fexofenadine Calibration Standards 
From Spiked HEK293 Cell Lysate. 
 
Concentration 
Added 
(ng/mL) 
Concentration 
Found (ng/mL) 
Precision 
(CV, %) 
Accuracy 
(%) 
1 1.06 2.6 106.5 
2 1.98 7.6 98.9 
5 4.73 2.1 94.5 
10 8.79 3.5 87.9 
50 53.5 1.7 106.9 
100 99.2 2.5 99.2 
500 498.6 0.7 99.7 
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Table 3.2: Intra- and Inter-Day Precision and Accuracy of the Method For 
Determining Fexofenadine Concentrations in HEK293 Cell Lysates. 
 
 Intra-day (n = 5)   
Concentration 
Added 
(ng/mL) 
Concentration 
found (mean) 
(ng/mL) 
Precision 
(CV, %) 
Accuracy 
(%) 
3 2.76 8.5 91.9 
75 72.8 3.5 97.0 
400 373.9 6.2 93.5 
500 450.6 2.5 90.1 
 
 Inter-day (n = 3)   
Concentration 
Added 
(ng/mL) 
Concentration 
found (mean) 
(ng/mL) 
Precision 
(CV, %) 
Accuracy 
(%) 
3 2.92 9.5 97.4 
75 76.3 3.4 101.7 
400 404.5 4.9 103.6 
500 500.8 4.3 100.2 
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3.3.5: Recovery. 
 
 Table 3.3 illustrates the recovery of fexofenadine from HEK293 cell lysate as 
compared to samples spiked in mobile phase.  The average recovery of fexofenadine 
from spiked cell culture matrix was from 86% to 123%.  With the exception of the LLOQ, 
all concentrations had standard deviations of recovery less than 20%. 
 
3.4: Discussion 
 
 Fexofenadine is a promising probe for transporter function both in vitro and 
especially in vivo.  In order to use fexofenadine as a probe of transporter function and 
measure fexofenadine transporter activity, a rapid, specific, and sensitive analytical 
method has been developed to meet this need.  Compared to other analytical methods, 
including HPLC with fluorescence detection (Coutant et al., 1991; Uno et al., 2004) and 
existing LC-MS/MS methods (Hofmann et al., 2002; Fu et al., 2004; Yamane et al., 2007) 
we are able to provide improved selectivity and sensitivity.  Our method yields a LLOQ of 
1 ng/mL, versus previously published LLOQs of greater than 1 ng/mL (Coutant et al., 
1991; Dresser et al., 2002; Hofmann et al., 2002; Fu et al., 2004; Yamane et al. 2007).  
While the LLOQ potentially could be extended to concentrations lower than 1 ng/mL 
fexofenadine, this was not necessary for our studies.  Uptake of fexofenadine via  
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Table 3.3: Recovery of Fexofenadine From HEK293 Cell Lysates. 
 
 
 
 
 
 
 
 
 
 
Concentration 
(ng/mL) 
Recovery 1 Recovery 2 Average Recovery 
1 75.7 96.3 86.0 
2 98.5 116.3 107.4 
5 106.8 104.9 105.9 
10 119.8 115.5 117.7 
50 105.3 77.3 91.3 
100 121.4 125.6 123.5 
500 117.1 105.7 111.4 
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transporters like OATP1A2 in transiently transfected cell models, similar to the model 
we employ, resulted in maximum fexofenadine concentrations of 1-3 µg/mL (Kim 2001); 
therefore, our method provides a level of sensitivity that will allow the study of even low 
efficiency transporter systems.  This method also meets the FDA guidelines for 
bioanalysis, with demonstrated accuracy within 90-110% of actual concentrations, 
precision of ± 10%, and recoveries greater than 75% from the HEK293 cell lysates 
(FDA 2001). 
 
 The choice of the internal standard for this method was a key step in the 
development and validation.  Our first approach was to use the pro-drug terfenadine as 
internal standard, since it shares extensive structural identity with fexofenadine.  We 
found, however, that the lack of the carboxyl group present in fexofenadine resulted in 
profoundly different chromatographic behavior, and that we experienced substantial 
carryover with terfenadine.  These problems ruled out the use of terfenadine as internal 
standard.  We then examined another antihistamine, cetirizine, as a possible internal 
standard based on similar structure and chemical properties with fexofenadine.  Use of 
cetirizine provided very similar chromatographic properties to those of fexofenadine and 
we observed no carryover or interference with the MRM channels between compounds.  
These observations supported our use of cetirizine as the internal standard for this 
assay. 
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 Although examination of fexofenadine transport is one goal of our studies, an 
additional goal is to employ fexofenadine as a probe for the detection and 
characterization of drug-drug interactions at specific transporters.  This will require the 
detection and quantitation of potentially competing drugs from cell lysate samples.  Our 
use of gradient elution is intended to support not only the analysis for fexofenadine, but 
also additional drugs for interaction studies.  We have performed initial studies to 
expand this assay to include the quantitation of four additional probe drugs: buspirone, 
caffeine, dextromethorphan, and losartan.  Use of a steep chromatographic gradient 
allows us to analyze five drugs and one internal standard in less than five minutes.  
Once the method is validated for these additional analytes it will allow us to characterize 
the kinetics of multiple substrates with transporters in a single sample and analytical 
run, greatly facilitating our investigations of drug-drug interactions. 
 
 This gradient method has been successfully used to characterize the kinetics of 
fexofenadine transport by HEK293 cells transiently-transfected with OATP1A2.    This 
validated method provides a rapid, sensitive, and specific analytical tool supporting the 
use of fexofenadine as a probe to study the contributions of individual membrane 
transporters in uptake and efflux of xenobiotics. 
 
3.5: Conclusion 
 We have presented a fully validated LC-MS/MS method for the quantification of 
fexofenadine in HEK293 cell lysate from in vitro transporter studies according to the 
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FDA guidelines for bioanalysis (FDA 2001).  Using a positive electrospray ionization 
mode, along with a commercially available internal standard (cetirizine), we have shown 
this method to be precise, accurate, and both sensitive and selective for the 
quantification of fexofenadine from cell culture uptake studies.  An easy and rapid 
sample preparation method and quick analysis time (less than 5 minutes) makes this 
suitable for high throughput bioanalysis. 
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Chapter 4 
Fexofenadine Drug-Drug Interactions at Organic Anion Transporting Polypeptide 
1A2 
 
4.1: Abstract 
 
Fexofenadine, a well-tolerated drug with pharmacokinetics controlled by 
transporters, may be a useful in vivo probe for human transporter function.  There is, 
however, uncertainty regarding the roles of specific transporters in fexofenadine 
pharmacokinetics.  We previously tested a probe drug cocktail containing fexofenadine, 
buspirone, caffeine, dextromethorphan, and losartan for the measurement of transporter 
and cytochrome P450 activities in humans. A pre-systemic drug-drug interaction was 
observed, resulting in a decrease in fexofenadine bioavailability when administered as 
part of the cocktail.  We have characterized fexofenadine transport by the two major 
intestinal OATP uptake transporters in vitro and have replicated the fexofenadine-probe 
drug interaction observed in vivo.  We conducted in vitro studies in OATP1A2-
expressing HEK293 cells and OATP2B1-expressing CHO cells.  We found that 
fexofenadine is transported by OATP1A2 (Km = 35 µM) but that fexofenadine is not 
effectively transported by OATP2B1.  Additional studies demonstrated that losartan, 
dextromethorphan, and buspirone each inhibited transport of fexofenadine by 
OATP1A2.  The efficient transport of fexofenadine by the intestinal uptake transporter 
OATP1A2 suggests that this transporter may be a major determinant of the 
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pharmacokinetics of oral fexofenadine.  Moreover, the inhibition of OATP1A2-
dependent transport of fexofenadine by three of the drugs in our probe drug cocktail 
explains the decrease in fexofenadine bioavailability seen in the clinical study.  Facile 
fexofenadine transport and the replication of the fexofenadine-probe drug interaction in 
this model system supports our conclusion that OATP1A2 is the major uptake 
transporter for fexofenadine absorption, and suggests that fexofenadine may be an 
effective probe drug for this transporter. 
 
4.2: Introduction 
 
Drug transporters like the members of the organic anion transporting polypeptide 
(OATP in humans, Oatp in other species) family play an important role in the 
absorption, distribution, and excretion of drugs.  OATPs are members of the SLCO 
superfamily, mediate the uptake of a wide number of substrates and have overlapping 
substrate specificity.  OATPs can facilitate cellular uptake, and thus enhance intestinal 
absorption, hepatic uptake, and uptake across the blood brain barrier of drugs and 
xenobiotics (Hagenbuch and Gui, 2008).  Among the eleven members of the OATP 
superfamily in humans OATP1A2 and 2B1 are the only OATPs associated with drug 
transport in the enterocyte (Hagenbuch and Meier, 2004; Glaeser et al., 2007). 
 
Fexofenadine pharmacokinetics are controlled by transporters rather than by 
metabolism (Lippert et al., 1995), suggesting that the pharmacokinetics of orally-
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administered fexofenadine could serve as an experimental probe of transporter activity 
in vivo, particularly in the enterocyte.  We began to investigate fexofenadine as a probe 
of transporter function by incorporating it into a cocktail with additional probe drugs for 
measurement of cytochrome P450 (CYP) activities.  These probe drugs (and the 
corresponding CYPs) were caffeine (CYP1A2), losartan (CYP2C9), dextromethorphan 
(CYP2D6), and buspirone (CYP3A4).  Initial validation of this probe cocktail included 
testing for pharmacokinetic interactions between the various probe drugs.  Transporter 
function was assessed based on the fexofenadine area under the curve (AUC).   
 
When fexofenadine AUC was compared in 14 subjects after administration of 
fexofenadine alone with administration of fexofenadine as part of the 5-drug cocktail, 
half of the subjects showed a 50% or greater decrease in the AUC for fexofenadine in 
the presence or the cocktail (Chapter 1).  Based on this observation we hypothesized 
that an enterocyte expressed OATP was involved in the absorption of fexofenadine, and 
that various CYP probes would interact with fexofenadine uptake and thus alter its 
absorption.  We tested this hypothesis by characterizing fexofenadine uptake using 
OATP1A2 and 2B1 expressing cell lines and determined the inhibitory effects of the 
probe drugs on this uptake.
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4.3: Results 
 
4.3.1: Inhibition of Estrone-3-Sulfate Transport by OATP1A2 in the Presence of 
Probe Drugs. 
 
In order to determine the effects of the probe drug cocktail components on 
OATP-mediated transport, we quantified uptake of the model substrate estrone-3-
sulfate in the absence and presence of each probe drug into OATP-expressing cells.  
HEK293 cells transiently expressing human OATP1A2 were exposed to 0.1 µM 3H-
estrone-3-sulfate alone or with 10 or 100 µM fexofenadine, losartan, dextromethorphan, 
buspirone, or caffeine for 30 seconds at pH 7.4 (Figure 4.1).  Caffeine had no effect at 
either concentration, however each of the other four drugs showed concentration 
dependent inhibition of estrone-3-sulfate uptake.  Fexofenadine, losartan and buspirone 
only inhibited estrone-3-sulfate uptake significantly at 100 µM.  Dextromethorphan was 
the strongest inhibitor resulting in 75% and 85% inhibition at 10 and 100 µM, 
respectively.
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4.3.2: Inhibition of Estrone-3-Sulfate Transport by OATP2B1 at Two pHs in the 
Presence of Probe Drugs. 
 
 The other OATP that is expressed in enterocytes is OATP2B1.  Therefore we 
quantified the effects of the probe drugs on estrone-3-sulfate uptake into cells 
expressing OATP2B1.  Experiments were performed at pH 7.4 and pH 5.5 since the 
range of substrates for OATP2B1 has been reported to be significantly broader at the 
lower pH (Kobayashi et al., 2003).  In contrast to OATP1A2, OATP2B1-mediated uptake 
of estrone-3-sulfate was only inhibited in the presence of 10 and 100 µM losartan while 
none of the other probe drug cocktail components showed any effect at either pH 7.4 
(Figure 4.2.1) or pH 5.5 (Figure 4.2.2). 
 
4.3.3: Fexofenadine Transport by OATP1A2 and OATP2B1. 
 
Given that drugs in the probe cocktail were capable of inhibiting OATP-mediated 
estrone-3-sulfate uptake and given that both OATP1A2 and OATP2B1 have been 
reported to transport fexofenadine, we next quantified fexofenadine uptake into 
OATP1A2- and OATP2B1-expressing cells.  HEK293 cells transiently expressing 
human OATP1A2 (Figure 4.3.1) or CHO cells stably expressing OATP2B1 (Figure 
4.3.2) were exposed to 1, 10, and 100 μM fexofenadine at pH 7.4 for 10 minutes and 
uptake was measured.  Uptake mediated by HEK293 cells that expressed OATP1A2 
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was clearly higher than uptake by the control HEK293 cells transfected with empty 
vector at all three concentrations measured (Figure 4.3.1).  Net uptake increased with 
increasing concentrations from about 10 to 150 pmoles and seemed to reach saturation.  
OATP2B1 mediated uptake however was between 100 and 150 fold lower (between 0.2 
and 3 pmoles) (Figure 4.3.2).  Although this uptake seemed to increase with increasing 
concentrations of fexofenadine, the absolute level was too low to determine the kinetic 
parameters and suggested that OATP2B1 may not be a major contributor to 
fexofenadine uptake system in enterocytes. 
 
4.3.4: Fexofenadine Transport Kinetics by OATP1A2. 
 
In order to characterize the transport kinetics of fexofenadine uptake by 
OATP1A2 we first determined the initial linear time range.  Uptake was linear up to 2.5 
minutes and therefore subsequent kinetic experiments were done at the 2 minute time 
point.  OATP1A2-expressing and control cells expressing only the empty vector were 
incubated with increasing concentrations of fexofenadine from 0.5-50 μM.  After 
subtracting the values obtained with the control cells, net OATP1A2-mediated transport 
showed clear saturation kinetics with a Km value of 35.1 μM and a Vmax value of 21 
pmol/mg*min for fexofenadine uptake (Figure 4.4). 
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Figure 4.1: 
 
 
 
 
 
 
 
 
 
 
Multiple Probe Drugs Inhibit OATP1A2-Mediated Transport of Estrone-3-Sulfate.  
HEK293 cells transiently expressing human OATP1A2 were exposed to 0.1 µM 3H-
estrone-3-sulfate (0.4 µCi/mL) alone or with 10 or 100 µM fexofenadine, losartan, 
dextromethorphan, buspirone, or caffeine for 30 seconds at pH 7.4.  After correction for 
protein, uptake into empty vector was subtracted to determine the net OATP1A2-
mediated uptake.  Values are expressed as pmol E3S/mg protein; each value is the 
mean ± SD of two independent experiments.  Asterisks represent statistically significant 
differences from the DMSO control (*, p < 0.05).
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Figure 4.2.1:  
 
 
 
 
 
 
 
 
 
 
Losartan Inhibits OATP2B1-Mediated Transport of Estrone-3-Sulfate at pH 7.4.  
CHO cells expressing human OATP2B1 were exposed to 0.1 µM 3H-E3S (0.4 µCi/mL) 
alone or with 10 or 100 µM fexofenadine, losartan, dextromethorphan, buspirone, or 
caffeine for 20 seconds at pH 7.4.  After correction for protein, uptake into wild-type 
control cells was subtracted to determine the net OATP2B1-mediated uptake at pH 7.4.  
Values are expressed as pmol E3S/mg protein; each value is the mean ± SD of two 
independent experiments.  Asterisks represent statistically significant differences from 
the DMSO control (*, p < 0.05). 
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Figure 4.2.2:  
 
 
 
 
 
 
 
 
 
 
Losartan Inhibits OATP2B1-Mediated Transport of Estrone-3-Sulfate at pH 5.5.  
CHO cells expressing human OATP2B1 were exposed to 0.1 µM 3H-E3S (0.4 µCi/mL) 
alone or with 10 or 100 µM fexofenadine, losartan, dextromethorphan, buspirone, or 
caffeine for 20 seconds at pH 5.5.  After correction for protein, uptake into wild-type 
control cells was subtracted to determine the net OATP2B1-mediated uptake at pH 5.5.  
Values are expressed as pmol E3S/mg protein; each value is the mean ± SD of two 
independent experiments.  Asterisks represent statistically significant differences from 
the DMSO control (*, p < 0.05). 
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Figure 4.3.1: 
 
 
 
 
 
 
 
 
 
 
 
 
Fexofenadine Transport by OATP1A2.  HEK293 cells transiently expressing human 
OATP1A2 were exposed to 1, 10, and 100 μM fexofenadine at pH 7.4 for 10 minutes to 
determine uptake of fexofenadine.  Uptake was corrected for empty vector and 
normalized to protein.  Fexofenadine appears to be transported by OATP1A2 in a 
concentration-dependent manner (Graph is a representative from at least three 
independent experiments; each point is an average of 3 wells ± SD).
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Figure 4.3.2: 
 
 
 
 
 
 
 
 
 
 
Fexofenadine Transport by OATP2B1.  CHO cells expressing human OATP2B1 were 
exposed to 1, 10, and 100 μM fexofenadine at pH 7.4 for 10 minutes to determine 
uptake of fexofenadine.  Uptake was corrected for empty vector and normalized to 
protein.  Fexofenadine appears to be minimally transported by OATP2B1 and not 
statistically significant (Graph is a representative from at least three independent 
experiments; each point is an average of 3 wells ± SD). 
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Figure 4.4: 
 
 
 
 
 
 
 
 
 
Concentration-Dependent Fexofenadine Uptake by OATP1A2.  HEK293 cells 
transiently expressing human OATP1A2 were exposed for 2 minutes to increasing 
concentrations of fexofenadine from 0.5-50μM.  Time dependent uptake of fexofenadine 
was linear over 2.5 minutes (data not shown).  Michaelis-Menten curve fitting was used 
to determine the Km value of 35.1± 5.8 μM with a Vmax of 21 ± 0.0018 pmol/mg*min 
(Graph representative of one assay, average of 3 wells ± SD; Km value representative of 
5 assays ± SEM).
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4.3.5: Probe Drug Cocktail Components Inhibit Fexofenadine Transport by 
OATP1A2. 
 
Given that OATP1A2 seems to play a dominant role in the uptake of 
fexofenadine, we examined the effects of the other probe drugs at 10 and 100 µM on 
OATP1A2-mediated fexofenadine uptake.  OATP1A2-expressing cells were exposed to 
30 µM fexofenadine alone (control) and in the presence of 10 or 100 µM losartan 
(Figure 4.5.1), dextromethorphan (Figure 4.5.2), or buspirone (Figure 4.5.3).  Both 10 
and 100 µM losartan significantly inhibited OATP1A2-mediated uptake of fexofenadine 
in a concentration dependent manner.  Ten and 100 µM dextromethorphan also 
significantly inhibited OATP1A2-mediated uptake of fexofenadine.  Only 100 µM 
buspirone inhibited OATP1A2-mediated uptake of fexofenadine in a significant manner 
as compared to the effects of losartan and dextromethorphan. 
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Figure 4.5.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration-Dependent Inhibition of the OATP1A2-Mediated Uptake of 
Fexofenadine by Losartan.  Uptake of 30 μM fexofenadine was measured alone and 
in the presence of 10 or 100 μM losartan for two minutes.  Uptake of fexofenadine by 
cells expressing empty vector was subtracted from uptake by cells expressing 
OATP1A2 and normalized to protein.  Asterisks represent statistically significant 
differences from the 30 μM fexofenadine control (*, p < 0.05).
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Figure 4.5.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration-Dependent Inhibition of the OATP1A2-Mediated Uptake of 
Fexofenadine by Dextromethorphan.  Uptake of 30 μM fexofenadine was measured 
alone and in the presence of 10 or 100 μM dextromethorphan for two minutes.  Uptake 
of fexofenadine by cells expressing empty vector was subtracted from uptake by cells 
expressing OATP1A2 and normalized to protein.  Asterisks represent statistically 
significant differences from the 30 μM fexofenadine control (*, p < 0.05).
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Figure 4.5.3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration-Dependent Inhibition of the OATP1A2-Mediated Uptake of 
Fexofenadine by Buspirone.  Uptake of 30 μM fexofenadine was measured alone and 
in the presence of 10 or 100 μM buspirone for two minutes.  Uptake of fexofenadine by 
cells expressing empty vector was subtracted from uptake by cells expressing 
OATP1A2 and normalized to protein.  Asterisks represent statistically significant 
differences from the 30 μM fexofenadine control (*, p < 0.05).
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4.4: Discussion: 
 
The major findings of the present study are the demonstration that: 1) OATP1A2 
is by far the most effective of the intestinal OATPs for facilitation of fexofenadine 
absorption, and 2) that the probe drug cocktail components losartan, dextromethorphan, 
and buspirone each can inhibit fexofenadine transport mediated by OATP1A2 in a 
concentration dependent manner. 
 
The first finding supports the hypothesis that OATP1A2 is the dominant 
transporter of fexofenadine in the enterocyte and is in agreement with the report of 
Cvetkovic et al. (1999) and Glaeser et al. (2007).  We were unable to characterize 
transport of fexofenadine by the other enterocyte-expressed OATP, namely OATP2B1 
(Figure 4.3.2).  Net transport of fexofenadine by OATP2B1-expressing cells was 50 to 
150 times less than fexofenadine transport seen in OATP1A2-expressing cells.  This is 
in marked contrast to the transport of the model substrate estrone-3-sulfate in these 
same OATP-expressing cells, where OATP2B1 was the more effective transporter 
(Figure 4.2.1 and 4.2.2).  Finally, we did not observe either a linear time dependence or 
clear concentration-dependent uptake of fexofenadine by OATP2B1, observations that 
would be expected if a saturable transporter was present. 
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Our findings with cells expressing OATP2B1 are in agreement with the report of 
Shimizu et al. (2005) who did not see significant transport of fexofenadine by OATP2B1.  
In addition, Glaeser et al. (2007) saw no uptake of fexofenadine by OATP2B1 in 
comparison to vehicle control.  In contrast, Imanaga et al. (2011) saw significant 
transport of fexofenadine in injected oocytes at pH 6.5.  They proposed a pH-
dependence to explain the differences between their result and that of the other 
laboratories.  It should be noted, however, that we examined OATP2B1-dependent 
fexofenadine uptake at both pH 7.4 and pH 5.5, and saw 50 to 100 times less 
fexofenadine transported than by its counterpart OATP1A2, regardless of pH.  These 
observations do not support a role for OATP2B1 as a major contributor to fexofenadine 
uptake from the intestine. 
 
Our characterization of OATP-dependent transport of fexofenadine instead 
suggests that OATP1A2 is the dominant transporter mediating absorption of this drug 
from the intestine.  The critical role of this transporter in controlling fexofenadine 
pharmacokinetics overall is supported by comparing the results of our probe drug 
interaction studies in vitro with previous drug-drug interactions in vivo.  We previously 
saw a marked decrease in fexofenadine Cmax and AUC in healthy subjects after 
administration of a probe drug cocktail containing buspirone, caffeine, 
dextromethorphan, fexofenadine, and losartan, relative to the values in the same 
subjects when fexofenadine was administered as a single drug (Reed et al., manuscript 
in preparation).  Neither plasma half-life nor urinary clearance of fexofenadine was 
altered by the observed drug-drug interaction.  This observation indicates a strong pre-
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systemic interaction between fexofenadine and one or more of the other probe drugs in 
the cocktail in vivo, resulting in decreased absorption of fexofenadine.  The ability to 
replicate a decrease in fexofenadine transport by OATP1A2 in vitro that mimics 
observations made in vivo is consistent with OATP1A2 being the dominant transporter 
modulating fexofenadine uptake. 
 
Multiple drugs are often dosed orally in humans, increasing the risk of significant 
drug-drug interactions.  As a result of this possible concurrent dosing, it is important to 
assess potential drug-drug interactions at both drug metabolizing enzymes and at 
membrane transporters.  There are numerous well-characterized probes for several of 
the major CYPs involved in drug metabolism; however there is a lack of well-tolerated 
and well-characterized probes for measurement of transporter function and drug-drug 
interactions in vivo (Frye et al., 1997; Christensen et al., 2003; Ryu et al., 2007).  
Fexofenadine is a potential probe for transporter activity based on the fact that it is not 
metabolized and is excreted unchanged.  Based on our findings reported here, it is 
reasonable to interpret decreases in both Cmax and AUC of oral fexofenadine, in the 
absence of changes in clearance, as a result of OATP1A2 inhibition.  Conversely, 
stimulation of P-gp would give the same result and such allosteric stimulation has been 
reported (Parasrampuria et al., 2001), however, P-gp inhibition is more widely 
documented as a drug-drug interaction (Wang et al., 2002; Dresser et al. 2003, Kamath 
et al. 2005, Yasui-Furukori et al. 2005, Shimizu et al., 2006) resulting in an increased 
Cmax and AUC for fexofenadine.  Acute drug-drug interactions resulting in decreased 
AUC for fexofenadine thus are most readily explained as resulting from OATP1A2 
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inhibition, whereas interactions increasing fexofenadine AUC would result from P-gp 
inhibition.  However if both OATP1A2 activity and P-gp activity are affected 
simultaneously by a drug-drug interaction, then the interpretation of our fexofenadine 
results are not as clear.  In addition, our interpretation is limited to acute, direct drug-
drug interactions.  Interpretation of results from chronic exposures, where not only direct 
interactions but effects on transporter expression also may be involved, would be even 
more complicated. 
 
Qiang et al. (2009) reported a fexofenadine-drug interaction in rats similar to 
what we have observed.  Oral dosing rats with the combination of fexofenadine and 
fluvastatin decreased fexofenadine AUC by 17-50% in rats, which is quite similar to our 
clinical findings.  The concurrent use of fluvastatin did not affect the intravenous 
pharmacokinetics of fexofenadine.  The marked decrease in oral AUC and Cmax values 
of fexofenadine with no change in tmax or t1/2  with fluvastatin pretreatment is likely due to 
the reduced intestinal absorption of fexofenadine rather than the enhanced systemic 
elimination by efflux transporters.  They hypothesize that the interaction seen between 
fexofenadine and fluvastatin may be occurring at an OATP since both drugs are 
substrates of multiple OATPs.  Our current study involving fexofenadine and the probe 
drug cocktail is the first to show an in vitro fexofenadine-drug interaction at an OATP 
that could explain an in vivo drug interaction in human subjects (Figure 4.5.1, 4.5.2, and 
4.5.3). 
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Fexofenadine interactions with dietary components also have been reported.  
Dresser et al. (2002 and 2005) have shown that fruit juices decrease oral bioavailability 
of fexofenadine.  It is likely that oral co-administration of fruit juice and fexofenadine 
results in a decreased AUC due to inhibition of OATP transporters in the small intestine.  
Concominant administration of fruit juice with oral fexofenadine creates a transient 
inhibitory effect; however it does not decrease expression of OATP1A2 at the mRNA 
level (Dresser et al., 2007).  Taken with the fexofenadine-fluvastatin interaction seen in 
rats as well as our own clinical observations, the fexofenadine-probe cocktail interaction 
is most likely to be occurring at an OATP in the enterocyte. 
 
Our results suggest that fexofenadine is transported predominantly by OATP1A2 
in the enterocyte.  Inhibition of fexofenadine transport by OATP1A2 with multiple 
components of a probe drug cocktail (losartan, dextromethorphan, buspirone) supports 
previous clinical observations and should be considered an important, previously 
unknown set of drug-drug interactions at an uptake transporter.  Moreover, these data 
suggest that we are able to replicate a decrease in fexofenadine transport in vitro that 
mimics observations made in vivo, thereby allowing us to determine the contribution of 
various OATPs to fexofenadine absorption and how drug-drug interactions can alter this 
absorption.  Although there are limitations, oral fexofenadine appears to be a 
reasonable probe for acute, inhibitory drug-drug- and drug-diet interactions at intestinal 
OATP1A2. 
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Chapter 5 
Multiple Organic Anion Transporting Polypeptides (OATPs) Play A Role in the 
Disposition of Losartan 
 
5.1: Abstract 
 
Although losartan clearance is controlled primarily by CYP2C9 activity, 
transporters are likely to play a role in losartan disposition because several OATPs have 
been shown to transport angiotensin II receptor antagonists.  We first tested losartan 
modulation of radiolabeled substrate transport with 4 members of the organic anion 
transporting polypeptides family.  Uptake of the model substrates estradiol-17β -
glucuronide (E17-βG) and estrone-3-sulfate (E3S) was measured using cell lines 
expressing each of these OATPs in the absence and presence of losartan.  Uptake of 
E3S by both OATP1A2 and OATP2B1 was inhibited by both 10 µM and 100 µM 
losartan; however uptake of E3S by OATP1B1 and OATP1B3 was inhibited only by 100 
μM losartan.  OATP1B1- and OATP1B3-mediated uptake of E17-βG was inhibited by 
losartan at both 10 and 100 μM losartan.  The ability of losartan to inhibit model 
substrate transport by four major OATPs indicates that losartan could be a substrate of 
these transporters.  Uptake of losartan by OATP1A2, OATP1B1, OATP1B3, and 
OATP2B1 was saturable at pH 7.4 with Km values of 58.2, 3.0, 17.6, and 16.6 μM 
respectively.  Apparent OATP2B1-mediated uptake of losartan was higher at pH 5.5 as 
compared to pH 7.4, but was not saturable.  These results demonstrate that losartan is 
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a substrate of OATP1A2, OATP1B1, 1B3, and 2B1, and thus these transporters may 
play a significant role in losartan disposition in both the small intestine and liver. 
 
5.2: Introduction 
 
The majority of drugs are dosed orally and in order for them to reach their target 
sites, they have to be absorbed in the small intestine and travel to the portal vein.  
These drugs are then transported to the liver and taken up into the hepatocytes where 
they can be metabolized by many enzymes including those in the cytochrome P450 
family (CYP).  Although some drugs can cross the plasma membrane by simple 
diffusion, the uptake of most drugs is controlled by transporters such as the organic 
anion transporting polypeptides (OATPs) that are expressed in epithelial cells 
throughout the body.  Enterocytes express OATP1A2 and OATP2B1 (Kobayashi et al., 
2003 and Glaeser et al., 2007) while in hepatocytes OATP1B1, OATP1B3 and 
OATP2B1 are expressed (Konig et al 2000a, Konig et al. 2000b, Kullak-Ublick et al. 
2001). 
 
Losartan, an angiotensin II receptor (Type AT1) antagonist is primarily converted 
by hepatic CYP2C9 to its active metabolite E3174 (Stearns et al., 1995; Yun et al., 
1995).  Therefore it has been used in various probe drug cocktails as a probe for 
CYP2C9 activity (Christensen et al., 2003; Ryu et al., 2007).  Although conversion to its 
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active metabolite E3174 provides an index of CYP2C9 activity, transporters may also 
play a role in losartan disposition.  It has been demonstrated that other sartans such as 
valsartan, telmisartan and olmesartan are substrates of liver-specific OATP1B1 and 1B3 
(Yamashiro et al., 2006, Ishiguro et al., 2006, Yamada et al., 2007).  Because this family 
of sartans is structurally similar, it suggested that losartan could also be a substrate of 
OATPs.  In addition, in a recent study where we characterized fexofenadine transport by 
OATPs (Chapter 4) we could demonstrate that losartan was an inhibitor of OATP-
mediated substrate uptake.  
 
Based on these observations, we hypothesized that both enterocyte- and 
hepatocyte-expressed OATPs could be involved in the uptake and disposition of 
losartan.  We tested this hypothesis by characterizing losartan uptake in vitro using cell 
lines expressing OATP1A2, OATP2B1, OATP1B1, or OATP1B3. 
 
5.3: Results 
 
5.3.1: Losartan Inhibits OATP-Mediated Substrate Transport. 
 
Previously, our lab investigated the effects of a probe drug cocktail containing 
fexofenadine, losartan, dextromethorphan, buspirone, and caffeine on OATP1A2- and 
OATP2B1-mediated estrone-3-sulfate transport (Chapter 4).  Interestingly, losartan 
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inhibited both OATP1A2- and OATP2B1-mediated transport of estrone-3-sulfate.  
Because losartan is metabolized to E3174 in the liver (Stearns et al., 1995; Yun et al., 
1995), OATPs expressed in hepatocytes may play a role in hepatocelullar losartan 
uptake.  In order to determine whether the observed inhibition of estrone-3-sulfate was 
specific for OATP1A2 and OATP2B1, we also quantified uptake of estrone-3-sulfate and 
estradiol-17β-glucuronide in the absence and presence of losartan into OATP1B1- and 
1B3-expressing CHO cells.  Uptake into CHO cells stably expressing human OATP1B1 
(Figure 5.1.1) or 1B3 (Figure 5.1.2) was inhibited by losartan.  While uptake of estradiol-
17β glucuronide was inhibited by both 10 and 100µM of losartan, estrone-3-sulfate 
uptake was only inhibited by 100µM losartan in both OATP1B1 and 1B3 expressing 
CHO cells.  
 
5.3.2: Losartan is Transported by Multiple OATPs. 
 
Given that losartan was capable of inhibiting substrate uptake by all four OATPs, 
we next tested whether losartan would be taken up by OATP1A2-, OATP2B1-, 
OATP1B1-, and OATP1B3-expressing cells.  Figure 5.2.1 illustrates that losartan is 
taken up into HEK293 cells transiently expressing human OATP1A2 in a concentration-
dependent manner.  In Figure 5.2.2 demonstrates that CHO cells stably expressing 
OATP2B1 (A, pH 7.4 and B, pH 5.5) also transport losartan in a concentration-
dependent manner, with greater losartan transport at pH 5.5.  OATP1B1 (A) and 
OATP1B3 (B) also transport losartan in a similar manner (Figure 5.2.3).
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Figure 5.1.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Losartan Inhibits OATP1B1-Mediated Transport of Estrone-3-Sulfate and 
Estradiol-17β-Glucuronide.  CHO cells stably expressing human OATP1B1 were 
exposed to 0.1 µM 3H-estrone-3-sulfate (0.4 µCi/mL) or 0.1 µM 3H-estradiol-17β-
glucuronide (0.4 µCi/mL) alone or with 10 or 100 µM losartan for 20 seconds.  After 
correction for protein, uptake into wild-type CHO cells was subtracted to determine the 
net estrone-3-sulfate (light gray bars) or estradiol-17β-glurcuronide (dark gray bars).  
Values are the mean ± SD of two independent experiments.
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Figure 5.1.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Losartan Inhibits OATP1B3-Mediated Transport of Estrone-3-Sulfate and 
Estradiol-17β-Glucuronide.  CHO cells stably expressing human OATP1B3 were 
exposed to 0.1 µM 3H-estrone-3-sulfate (0.4 µCi/mL) or 0.1 µM 3H-estradiol-17β-
glucuronide (0.4 µCi/mL) alone or with 10 or 100 µM losartan for 20 seconds.  After 
correction for protein, uptake into wild-type CHO cells was subtracted to determine the 
net estrone-3-sulfate (light gray bars) or estradiol-17β-glurcuronide (dark gray bars).  
Values are the mean ± SD of two independent experiments.
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Net uptake increased with increasing concentrations of losartan for all OATPs tested 
and appeared to reach saturation.  These results demonstrate that losartan is a 
substrate of the four tested OATPs. 
 
5.3.3: Losartan Kinetics by OATPs Expressed in the Enterocyte. 
 
Next we characterized the transport kinetics of losartan by OATP1A2 and 
OATP2B1 which are expressed in enterocytes.  We first established the initial linear 
range of uptake which was 40 seconds for OATP1A2 and 1 minute for OATP2B1.  
Therefore, concentration dependent uptake of losartan was determined at 20 seconds 
for OATP1A2 and 30 seconds for OATP2B1.  In Figure 5.3 A, kinetics of OATP1A2-
mediated losartan uptake are shown.  Transport showed clear saturation with a Km 
value of 58.2 μM and a Vmax value of 12 pmol/mg*min.  For OATP2B1, a Km value of 
16.6 μM and a Vmax value of 14 pmol/mg*min was determined (Figure 5.3, B).  
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Figure 5.2.1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Losartan is a Substrate of OATP1A2.  HEK293 cells transiently expressing human 
OATP1A2 were exposed to 1, 10, and 100 μM losartan for 10 minutes and uptake was 
determined.  Uptake was normalized to protein.  Values are the mean ± SD of three 
independent experiments.  
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Figure 5.2.2: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Losartan is a Substrate of OATP2B1 at Two pHs.  CHO cells expressing human 
OATP2B1 were exposed to 1, 10, and 100 μM losartan for 10 minutes at pH 7.4 (A) or 
pH 5.5 (B) and uptake was determined.  Uptake was normalized to protein.  Values are 
the mean ± SD of three independent experiments.
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Figure 5.2.3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Losartan is a Substrate of OATP1B1 and 1B3.  CHO cells expressing human 
OATP1B1 (A) or OATP1B3 (B) were exposed to 1, 10, and 100 μM losartan for 10 
minutes and uptake was determined.  Uptake was normalized to protein.  Values are 
the mean ± SD of three independent experiments.
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Figure 5.3: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentration-Dependent Uptake of Losartan by OATP1A2 and OATP2B1.  Cells 
expressing human OATP1A2 (A) were exposed for 30 seconds to 5-500 μM losartan.  
Cells expressing human OATP2B1 (B) were exposed for 30 seconds to 1-100 μM 
losartan at pH 7.4.  Michaelis-Menten curve fitting was used to determine the Km values 
of 58.2 μM for OATP1A2 and 16.6 μM for OATP2B1.  Uptake was corrected for empty 
vector and normalized to protein.  Graphs representative of one assay, average of 3 
wells ± SD; Km value representative of 3 assays ± SEM.
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5.3.4: Losartan Kinetics by OATPs Expressed in the Hepatocyte. 
 
For OATP1B1- and OATP1B3-mediated uptake of losartan, transport was linear 
over the first minute and therefore experiments were performed at 30 seconds.  Figure 
5.4 shows that after subtracting the values obtained with the control cells, net 
OATP1B1-mediated transport showed clear saturation kinetics with a Km value of 3.0 
μM and a Vmax value of 20 pmol/mg*min (A), whereas OATP1B3-mediated uptake of 
losartan had a Km value of 17.6 μM and a Vmax value of 120 pmol/mg*min (B).
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Figure 5.4: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5: Concentration-Dependent Losartan Uptake by OATP1B1 and 
OATP1B3.  Cells expressing human OATP1B1 (A) were exposed for 30 seconds to 0.1-
10 μM losartan.  Cells expressing human OATP1B3 (B) were exposed for 30 seconds to 
1-100 μM losartan.  Michaelis-Menten curve fitting was used to determine the Km values 
of 3.0 μM for OATP1B1 and 17.6 μM for OATP1B3.  Uptake was corrected for empty 
vector and normalized to protein.  Graphs representative of one assay, average of 3 
wells ± SD; Km value representative of 3 assays ± SEM.
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5.4: Discussion 
 
 Telmisartan is quite lipophilic (Strohmenger et al., 1998) and has been shown to 
be transported by OATP1B3 (Yamada et al., 2007), olemesartan is administered as a 
pro-drug (Nakagomi-Hagihara et al., 2006) that is rapidly metabolized in the small 
intestine, and little is known about how valsartan is absorbed after a single dose.  Since 
losartan is dosed orally and the most structurally similar to valsartan, we hypothesize 
that losartan utilizes OATPs present in enterocytes to cross the gut wall and enter portal 
circulation prior to metabolism in the liver.  In this study we demonstrated that losartan 
can inhibit transport of estrone-3-sulfate and estradiol-17β glucuronide in a 
concentration dependent manner, and that OATP1A2, OATP2B1, OATP1B1 and 
OATP1B3 are all capable of transporting losartan in both a time- and concentration-
dependent manner. 
 
Inhibition of model substrate transport was an indication that losartan may be 
transported by various OATPs involved in absorptive processes in the small intestine 
and liver.  Significant inhibition of estrone-3-sulfate transport was seen at both 
concentrations of losartan for OATP1A2 and OATP2B1 (Chapter 4), however, only at 
100 µM losartan did we see inhibition of OATP1B1- or OATP1B3-mediated transport of 
estrone-3-sulfate (Figure 5.1.1 and 5.1.2).  This variation in inhibition may be due to 
differing substrate affinities for OATP1B1 and OATP1B3.  Therefore we also tested if an 
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additional substrate, estradiol-17β-glucuronide, could be modulated by losartan and 
observed significant concentration dependent inhibition by losartan at 10 and 100 µM. 
 
Since OATP1A2 and 2B1 are capable of transporting losartan in a time and 
concentration-dependent manner (Figure 5.3), it seems likely that these two OATPs 
play a role in losartan absorption and disposition in the gut.  As previously mentioned, 
other angiotensin II receptor antagonists are substrates of OATP1B1 and 1B3 and they 
also share structural similarity with losartan.  Since losartan is metabolized to E3174 in 
the liver prior to exerting its anti-hypertensive effects, we hypothesized that OATP1B1 
and/or OATP1B3 would be capable of transporting losartan into hepatocytes.  We were 
then able to show that losartan is transported by OATP1B1 and OATP1B3 in a time and 
concentration-dependent manner (Figure 5.4) and plays a role in the uptake of losartan 
into the liver for metabolism by CYP2C9. 
 
Based on the Michaelis constants calculated here, OATP2B1 (Km = 16.6 µM) has 
a greater affinity for losartan than OATP1A2 (Km = 58.2 µM) and OATP1B1 (Km = 3.0 
µM) has a greater affinity for losartan than OATP1B3 (Km = 17.6 µM).  This implies that 
if drug-drug interactions involving OATP transport of losartan were to occur, it would 
more likely be at the OATPs with the lesser affinity for losartan.  Those substrates with 
larger Km values and therefore less affinity for the substrate bind the substrate to a 
lesser degree and can be sites of drug-drug interactions.  Therefore OATP1A2 and/or 
OATP1B3 would be sites for drug-drug interactions based on lesser affinities for 
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losartan.  However, since substrate specificity varies between OATPs as well as 
overlaps, assessing drug-drug interactions with losartan may require multiple 
substrates. 
 
The inability to saturate OATP2B1 at pH 5.5 appears to be a direct consequence 
of the chemistry of losartan, and the tetrazole ring in particular.  The tetrazole ring on 
losartan has a pKa of 4.89, leaving it neutrally protonated at pH 7.4.  Decreasing the pH 
to 5.5 in order to broaden OATP2B1 substrate specificity increases the amount of 
uncharged losartan present in the system.  At pH 5.5 80-times more losartan is 
uncharged and can freely diffuse across the cell membrane as compared to pH 7.4.  
This can be better illustrated in Figure 5.2.2, where empty vector expressing cells of 
OATP2B1 (A) contain approximately 10 pmol losartan at pH 7.4, whereas empty vector 
expressing cells of OATP2B1 at pH 5.5 contain 50 times more losartan at pH 5.5 (B).   
 
In conclusion, the transport of losartan by major OATPs expressed in the 
enterocyte and in the hepatocyte suggests that these proteins may play a significant 
role in losartan disposition, by playing roles in its uptake from the gut (absorption) and 
uptake into the liver (distribution) for metabolism.  The multi-specific, overlapping 
substrate specificity of OATPs and the ability of losartan to be transported by multiple 
OATPs in both the enterocyte and hepatocyte has direct implications for drug-drug 
interactions involving this probe drug. 
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Chapter 6 
OATP1A2 Single Nucleotide Polymorphisms and Their Effect on Fexofenadine 
Transport and Drug-Drug Interactions 
 
6.1: Abstract 
 
 OATP1A2 is capable of transporting the H1-receptor antagonist fexofenadine in 
both a time and concentration dependent manner.  Because OATP1A2 is multi-specific 
and capable of transporting a wide range of drugs, xenobiotics, and endogenous 
compounds, either drug-drug or drug-diet interactions may alter its function.  Genetic 
polymorphisms also can alter transporter function.  We have observed fexofenadine-
drug interactions in vivo and could explain them by OATP1A2 inhibition in vitro (Chapter 
4).  We observed that buspirone, dextromethorphan, and losartan, components of the 
Kansas Cocktail, are capable of inhibiting fexofenadine transport by OATP1A2.  To 
identify whether or not OATP1A2 single nucleotide polymorphisms could play a role in 
the fexofenadine-drug interaction seen in vivo, we performed site-directed mutagenesis 
and created three OATP1A2 mutants (Ile13Thr, Arg168Cys, and Glu172Asp) known to 
alter substrate transport.  To determine the effects of each mutation on OATP1A2 
function and drug-drug interactions, we expressed these mutants in HEK293 cells and 
measured uptake of 30 µM fexofenadine for 2 minutes alone and in the presence of low 
and high concentrations of buspirone, dextromethorphan, and losartan.  While the 
mutants functioned as expected with regards to fexofenadine transport, the presence of 
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the mutation did not alter the observed drug-drug interactions seen previously with 
OATP1A2 and components of the Kansas Cocktail.  Together these data suggest that 
the fexofenadine-drug interaction seen in vivo is likely a result of a direct drug-drug 
interaction and not due to a single nucleotide polymorphism. 
 
6.2: Introduction 
 
The absorption of drugs dosed orally depends on passive diffusion or carrier 
mediated transport through cell membranes.  Organic anion transporting polypeptides 
(OATPs) are a family of multi specific membrane uptake transporters capable of 
transporting a wide range of drugs, xenobiotics, and endogenous compounds into cells 
(Hagenbuch and Meier, 2004).  Organic anion transporting polypeptide 1A2 (OATP1A2) 
is primarily expressed in epithelial cells of the kidney, bile ducts, intestine, and in 
endothelial cells of the blood-brain barrier (Gao et al., 2000; Su et al., 2004; Lee et al., 
2005). Because OATP1A2 is known to be a drug uptake transporter with broad 
substrate specificity that includes many clinically used drugs it likely plays an important 
role in tissue-specific disposition, pharmacokinetics, and toxicity of xenobiotics.  
Therefore, genetic variations in SLCO1A2 may alter transport kinetics or drug-drug and 
drug-diet interactions, and thus may have important implications in regard to the 
disposition of drugs. 
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Direct effects of genetic variants of OATP1A2 on transporter function have been 
described.  Lee et al. (2005) identified 6 non-synonymous single polymorphisms (SNPs) 
within the coding region of SLCO1A2 (Ile13Thr, Asn128Tyr, Asn135Ile, Glu172Asp, 
Ala178Thr, and Thr668S).  In vitro functional studies revealed that the Asn135Ile and 
Glu172Asp variants had reduced uptake capacity for estrone-3-sulfate, deltorphin II, 
and [D-penicillamine2,5]-enkephalin.  Other variants had substrate specific altered 
transport activity.  Kinetic analysis of the transport data indicated that mutations at 
amino acids 128, 135, 172, 187, and 668 have functional consequences (Lee et al., 
2005). 
 
Badagnani et al. (2006) described seven protein-altering OATP1A2 variants 
found in 270 ethnically diverse samples.  Four of the seven variants (Ile13Thr, 
Arg168Cys, Glu172Asp, and Thr668Ser) were found to exhibit altered transport of 
estrone-3-sulfate or methotrexate.  Because these genetic variants exhibit altered 
transport properties, we wondered whether these variants also would alter drug-drug 
interactions at OATP1A2.  We chose to examine this possibility using fexofenadine as 
the substrate and constructed the OATP1A2 mutants Ile13Thr, Arg168Cys, and 
Glu172Asp.  In order to compare the effect of probe dugs on the function of wild-type or 
mutant OATP1A2, wild-type OATP1A2 and the three variantes were expressed in 
HEK293 cells and uptake of fexofenadine was determined in the absence and presence 
of the CYP probe drugs buspirone, dextromethorphan, and losartan. 
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6.3 Results: 
 
6.3.1 Alterations in Fexofenadine Uptake by OATP1A2 Variants. 
 
 It has been shown that OATP1A2 variants with non-synonymous single 
nucleotide polymorphisms have altered transport of estrone-3-sulfate and methotrexate 
(Lee et al., 2005; Badagnani et al., 2006).  We decided to test three of these OATP1A2 
variants, Ile13Thr, Arg168Cys, and Glu172Asp, for their ability to transport 0.1 µM 3H-
estrone 3-sulfate (A) and 30 µM fexofenadine (B) as compared to wild-type OATP1A2.  
Figure 6.1 illustrates that Ile13Thr transported both substrates to the same extent as 
wild-type OATP1A2.  Arg168Cys transported both substrates to only about 50% of the 
rate obtained with wild-type OATP1A2 while Glu172Asp showed a substrate specific 
effect.  It had similar estrone-3-sulfate uptake as wild-type OATP1A2 but uptake of 
fexofenadine was reduced by 80% when compared to wild-type control. 
 
6.3.2 Fexofenadine-Losartan Drug-Drug Interactions and OATP1A2 Variants. 
 
 As shown in Chapter 4, buspirone, dextromethorphan and losartan, three 
components of the Kansas Cocktail, were capable of inhibiting fexofenadine transport 
by OATP1A2 in vitro.  Figure 6.2 demonstrates that losartan was able to inhibit transport 
of 30 µM fexofenadine by wild-type OATP1A2 (A) as well as by the three variants at 
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both 10 and 100 µM concentrations of losartan.  The different OATP1A2 variants were 
inhibited to at least the same degree as wild-type OATP1A2, including Ile13Thr (B).  
Inhibition of Arg168Cys- and Glu172Asp-mediated fexofenadine transport (C and D) 
was even more complete than inhibition of wild-type OATP1A2 probably due to the fact 
that fexofenadine uptake by these two variants was reduced overall.  Taken together, 
the introduction of OATP1A2 mutations does not seem to alter the fexofenadine-
losartan interaction seen previously.
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Figure 6.1:  
 
 
 
 
 
 
 
 
 
 
 
 
Alterations in Substrate Uptake by OATP1A2 Variants.  HEK293 cells transiently 
expressing OATP1A2 were incubated with 0.1 μM 3H-estrone-3-sulfate (A) for 5 minutes 
or 30 μM fexofenadine (B) for 2 minutes at 37°C.  After correction for protein, uptake 
into empty vector cells was subtracted to obtain net uptake.  Each value is the mean ± 
SEM of three independent experiments.
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Figure 6.2: 
 
 
 
 
 
 
 
 
 
 
 
Fexofenadine-losartan drug-drug interactions with OATP1A2 variants.  HEK293 
cells transiently expressing WT OATP1A2 (A), Ile13Thr variant (B), Arg168Cys (C), and 
Glu172Asp (D) were incubated with 30 μM fexofenadine alone (control) or in the 
presence of 10 or 100 µM losartan for 2 minutes at 37°C.  After normalizing to protein 
and subtracting the values obtained in cells expressing the empty vector, uptake of 
fexofenadine was expressed as a percentage of wild-type.  Each value is the mean ± 
SEM of three independent experiments. 
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6.3.3 Fexofenadine-Dextromethorphan Drug-Drug Interactions and OATP1A2 
Variants. 
 
 Dextromethorphan, a CYP2D6 probe, was capable of significant inhibition of 30 
µM fexofenadine transport by WT OATP1A2 at 10 and 100 µM concentrations of 
losartan (Figure 6.3, A).  The hyperfunctional Ile13Thr variant does not alter the 
inhibition of fexofenadine transport by dextromethorphan in comparison to WT 
OATP1A2 expressing cells (B).  Hypofunctional variants Arg168Cys and Glu172Asp (C 
and D) transport less fexofenadine overall, therefore their percent inhibition by 10 and 
100 µM dextromethorphan appears more significant because these mutants transport 
less fexofenadine overall.  Taken together, the introduction of OATP1A2 mutations does 
not seem to alter the fexofenadine-dextromethorphan interaction seen previously. 
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Figure 6.3: 
 
 
 
 
 
 
 
 
 
 
 
Fexofenadine-dextromethorphan drug-drug interactions with OATP1A2 variants.  
HEK293 cells transiently expressing WT OATP1A2 (A), Ile13Thr variant (B), Arg168Cys 
(C), and Glu172Asp (D) were incubated with 30 μM fexofenadine alone (control) or in 
the presence of 10 or 100 µM dextromethorphan for 2 minutes at 37°C.  After 
normalizing to protein and subtracting the values obtained in cells expressing the empty 
vector, uptake of fexofenadine was expressed as a percentage of wild-type.  Each value 
is the mean ± SEM of three independent experiments.
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6.3.4 Fexofenadine-Buspirone Drug-Drug Interactions and OATP1A2 Variants. 
 
 Buspirone, a CYP3A4 probe, was capable of significant inhibition of 30 µM 
fexofenadine transport by WT OATP1A2 at 10 and 100 µM concentrations of losartan 
(Figure 6.4, A).  The hyperfunctional Ile13Thr SNP does not alter the inhibition of 
fexofenadine transport by busprione in comparison to WT OATP1A2 expressing cells 
(B).  Hypofunctional variants Arg168Cys and Glu172Asp (C and D) transport less 
fexofenadine overall, therefore their percent inhibition by 10 and 100 µM buspirone 
appears more significant because these mutants transport less fexofenadine overall.  
Taken together, the introduction of OATP1A2 mutations does not seem to alter the 
fexofenadine-busprione interaction seen previously. 
 
6.4: Discussion 
 
In this study we demonstrated that three OATP1A2 variants are capable of 
transporting both estrone-3-sulfate and fexofenadine in an altered manner from that of 
wild-type OATP1A2.  While we saw differences in fexofenadine transport by the 
OATP1A2 variants, the fexofenadine-drug interactions were not significantly affected by 
the presence of a single nucleotide polymorphism, indicating that the fexofenadine-drug 
interaction seen in Chapter 4 is not due to genetic variation, but the interaction between 
one or more probe drugs and fexofenadine at OATP1A2. 
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Figure 6.4: 
 
 
 
 
 
 
 
 
 
 
 
Fexofenadine-buspirone drug-drug interactions with OATP1A2 variants.  HEK293 
cells transiently expressing WT OATP1A2 (A), Ile13Thr variant (B), Arg168Cys (C), and 
Glu172Asp (D) were incubated with 30 μM fexofenadine alone (control) or in the 
presence of 10 or 100 µM busprione for 2 minutes at 37°C.  After normalizing to protein 
and subtracting the values obtained in cells expressing the empty vector, uptake of 
fexofenadine was expressed as a percentage of wild-type.  Each value is the mean ± 
SEM of three independent experiments.
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 Site directed mutagenesis allowed us to create three OATP1A2 variants seen 
previously in human subjects, Ile13Thr, Arg168Cys, and Glu172Asp (Lee et al., 2005; 
Badagnani et al., 2006) and examine the effects of these mutations on the transport of 
fexofenadine.  We saw quantitative similarities in how all three variants transported 
estrone-3-sulfate when compared to results by Badagnani et al (2006), with the Ile13Thr 
mutant being hyperfunctional and the Arg168Cys mutant showing hypofunctionality with 
transport of 0.1 µM estrone-3-sulfate.  There were no observed changes in Vmax (as 
reported by Badagnani et al.) associated with Glu172Asp; however, since we only 
examined one concentration of estrone-3-sulfate, we would not expect to see changes 
in capacity of transport (Figure 6.1, A).  When examining transport of fexofenadine by 
OATP1A2 variants, there was no difference in transport by Ile13Thr when compared to 
wild-type OATP1A2 and both Arg168Cys and Glu172Asp demonstrate hypofunctionality 
in transport (Figure 6.1, B).  This suggests that while each OATP1A2 mutant is capable 
of altering substrate transport, that the degree of transport is somewhat substrate 
specific. 
 
 While we saw differences in fexofenadine transport by OATP1A2 variants, the 
fexofenadine-drug interactions were not significantly affected by the presence of a 
single nucleotide polymorphism.  Losartan was capable of inhibiting transport of 
fexofenadine by WT OATP1A2, as well as Ile13Thr, Arg168Cys, and Glu172Asp; 
however, there was no enhanced inhibition or stimulation of uptake in the presence of 
these mutations (Figure 6.2).  Since variants Arg168Cys and Glu172Asp have reduced 
transport of fexofenadine, the degree of inhibition appears greater than wild-type, yet 
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the phenomenon observed is less fexofenadine transported, but the same percentage 
of inhibition by losartan.  Similar trends can also be seen for dextromethorphan-
fexofenadine interactions (Figure 6.3) and buspirone-fexofenadine interactions (Figure 
6.4).  While each OATP1A2 variant has different affinity or capacity for fexofenadine, it 
the fexofenadine-drug interaction is not altered by the presence of a single nucleotide 
polymorphism. 
 
 Genotypic analysis of the OATP1A2 variants showed that allelic frequency was 
dependent on ethnicity.  The hyperfunctional mutant (Ile13Thr) examined by both Lee et 
al. (2005) and Badagnani et al (2006) is present in European-American populations at 
11.1% and 16.3% respectively.  The novel hypofunctional Arg168Cys mutant is present 
in 0.6% of European Americans sampled, and the Glu172Asp hypofunctional mutant is 
present in European American populations at 5.3% and 1.9%, respectively (Lee et al., 
2005; Badagnani et al., 2006).  In examining the allelic frequencies of these mutations 
and their lack of effect in our in vitro fexofenadine-drug interaction studies, it is highly 
unlikely that the majority of our sample population falls into the ethnic groups with the 
most diversity and alteration of transport. 
 
  In summary, our studies suggest that protein-altering variants in OATP1A2 do 
not play a role in inter-individual variability of fexofenadine-probe drug interactions.  
While transport of fexofenadine as a substrate is altered by three known variants of 
OATP1A2 (Ile13Thr, Arg168Cys, and Glu172Asp), they do not contribute significantly to 
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fexofenadine transport inhibition by losartan, dextromethorphan, or buspirone.  
Decreases in AUC and Cmax of fexofenadine when dosed as part of the Kansas Cocktail 
are likely to occur from a direct drug-drug interaction at OATP1A2 versus a genetic 
polymorphism.  Differing expression levels of WT OATP1A2 or variation in fexofenadine 
bioavailabilty between human subjects may potentially play a role in the fexofenadine-
drug interaction observed previously, but not the three SNPs examined here. 
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Chapter 7 
Summary and Discussion 
 
7.1: Significance 
 
Inter- and intra-individual variability in responses to drugs poses a major clinical 
challenge that needs to be managed, often arising from differences in pharmacokinetics 
of the drug. Understanding the cause, being able to predict changes, and managing 
variation in pharmacokinetic responses requires the utilization of better experimental 
approaches and investigation of mechanisms responsible for these phenomena.  Probe 
drugs represent a potentially valuable approach to the study of variability in 
pharmacokinetics; however, there are few specific probe drugs for Phase 2 enzymes or 
for transporters that have been well characterized.  Membrane transporters are proteins 
that transport drugs across cellular membranes and play an integral role in the 
absorption, distribution, metabolism, and excretion of drugs.  Due to their important role 
in the disposition of drugs, changes in transport activity ultimately result in alteration of 
the pharmacokinetics of drugs, thereby impacting their effects. 
 
Active and facilitative drug transporting molecules, like P-glycoprotein and 
organic anion transporting polypeptides (OATPs), play an important role in the 
absorption, distribution, metabolism, and excretion of drugs.  P-glycoprotein is a 
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membrane transport efflux protein that is highly expressed throughout the body and 
contributes to the decreases in both the absorption and the distribution of drugs to 
organs, tissues, and cells.  Opposing P-glycoprotein is the OATP family of transporters, 
which act as uptake transporters and facilitate absorption and distribution of 
endogenous hormones, drugs, and xenobiotics throughout the body.  Of particular 
interest, OATP1A2 is expressed in many tissues including the apical membrane of the 
small intestine, blood brain barrier, kidney, and cholangiocytes of the liver. 
 
After a drug is given orally, it must move through several biological membranes 
to exert its pharmacological effect.  Since OATPs are localized to cell membranes and 
actively move drugs through such barriers, they play a role in pre-systemic drug-drug 
interactions and first-pass effects.  Polymorphisms in OATPs have been associated with 
altered pharmacokinetics of many substrates, including methotrexate, deltorphin, and 
estrone-3-sulfate, demonstrating their significance to drug disposition.  Many drug-drug 
and drug-food interactions at OATPs can also alter the pharmacokinetic profiles of 
many drug substrates, leading to decreased efficacy or increased toxicity.  Inclusion of 
fexofenadine as a probe for transport activity in the Kansas Cocktail resulted in a 
previously unreported fexofenadine-drug interaction.  Since fexofenadine is minimally 
metabolized, its kinetics are controlled by transporters; however, there is still uncertainty 
in regards to which membrane transporters are controlling fexofenadine 
pharmacokinetics and to what extent. 
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In this dissertation, the studies presented were designed to better elucidate the 
OATPs involved in fexofenadine pharmacokinetics, as well as define the exact nature of 
the fexofenadine-drug interaction seen clinically with the Kansas Cocktail.  To do this, I 
formulated my central hypothesis around fexofenadine being primarily transported by 
OATP1A2 and that the fexofenadine-drug interaction was occurring at this transporter.  
This hypothesis was then tested via four specific aims: first, development of a sensitive, 
rapid, and specific method for quantifying fexofenadine from cell culture lysates; 
second, definition and characterization of the kinetics of fexofenadine with human OATP 
uptake transporters known to be expressed in the enterocyte and the hepatocyte; third, 
identification of probe drug(s) interacting with fexofenadine at defined transporter(s); 
and fourth, exploration of the effect of OATP1A2 variants on fexofenadine transport 
kinetics and fexofenadine-probe drug interactions. 
 
7.2: Specific Aim 1 
 
 In my first Specific Aim, I developed and fully validated a high performance liquid 
chromatography-tandem mass spectrometry method for quantification of fexofenadine 
in mammalian cell lysates, with cetirizine used as the internal standard.  Using the FDA 
Guidelines for Bioanalysis (FDA, 2001) as a guide, we determined the linearity, 
accuracy, precision, and recovery of fexofenadine in both mobile phase and HEK293 
cell lysates.  This method was then applied to the analysis of fexofenadine in cell 
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lysates from in vitro transporter studies, and further developed to measure other probe 
drugs to support drug-drug interaction studies in these model systems. 
 This study showed that the most sensitive transitions were 502.17/466.2 for 
fexofenadine and 389.09/201.1 for the internal standard cetirizine.  We optimized 
chromatographic conditions by testing a variety of aqueous and organic mobile phases.  
Based on sensitivity, peak shape for the analyte and internal standard, and on overall 
run time, we chose 7.5 mM ammonium formate, pH 5 as an aqueous mobile phase and 
50/50 (v/v) acetonitrile:methanol mixture for the organic component.  Use of a gradient 
system allowed elution of fexofenadine at 2.48 minutes and the internal standard at 2.66 
minutes with a total run time of less than five minutes. 
 
 Method selectivity was examined by analyzing blank cell culture matrix samples 
and matrix spiked only with internal standard.  There was no endogenous matrix 
interference at the retention times of the fexofenadine or cetirizine.  Similarly, the 
cetirizine (IS) does not show any crossover in the MRM of fexofenadine.  The assay was 
sensitive for fexofenadine at concentrations as low as 1 ng/mL, which was also the lower 
limit of quantitation (LLOQ) of fexofenadine. The calibration curve for fexofenadine 
extracted from HEK293 cell lysates was linear over the concentration range of 1-500 
ng/mL fexofenadine, with an r2 of 0.99.   
 
 Fexofenadine quantitation at 1 ng/mL was accomplished with a precision of 2.6% 
and a mean accuracy of 106.5%, well within the limits for defining the LLOQ.  Similarly, 
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the precision and accuracy of each concentration of fexofenadine in the calibration curve 
met the FDA criteria for bioanalytical method validation.  The inter-day coefficient of 
variation (CV) for the lowest QC standard (3 ng/mL) in cell lysate is 9.5% and the 
between batch accuracy was 97.4%.  Within the batches, the low QC standard had a CV 
of 8.5% and the accuracy was 91.9%.  For the middle and upper quantification levels, 
ranging from 75-500 ng/mL, the precision ranged from 2.5-6.2% and the accuracy from 
90.1-97.0% within batch.  Between batches, the precision ranged from 3.4-4.9% and the 
accuracy from 97.4-103.6% in HEK293 cell lysate.  As a final experiment, I looked at 
recovery of fexofenadine from cell lysates as compared to blank matrix.  The average 
recovery of fexofenadine was from 86% to 123% and with the exception of the LLOQ; all 
concentrations had standard deviations of recovery less than 20%. 
 
 My first specific aim clearly demonstrates that we have developed a highly 
sensitive and specific assay for the quantification of fexofenadine in cell lysates.  In 
order to use fexofenadine as a probe of transporter function and measure fexofenadine 
transporter activity, a rapid, specific, and sensitive analytical method has been 
developed to meet this need.  Compared to other analytical methods, including HPLC 
with fluorescence detection and existing LC-MS/MS methods, this aim was able to 
provide improved selectivity and sensitivity.  Our method yields a LLOQ of 1 ng/mL, 
versus previously published LLOQs of greater than 1 ng/mL.  We were also able to 
expand the method to include other probe drugs, including buspirone, caffeine, 
dextromethorphan, and losartan.  Utilization of the same gradient and mobile phases, 
sample preparation procedure, and internal standard, as well as a run time under 5 
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minutes, made this method ideal for measuring the effects of the Kansas Cocktail on 
transporter activity. 
 
7.3: Specific Aim 2 
 
 In the first Specific Aim, we addressed a need to develop a specific and sensitive 
method for measuring fexofenadine in HEK293 cell culture lysates from transporter 
experiments.  In the second Specific Aim, we wanted to define and characterize the 
kinetics of fexofenadine with OATP uptake transporters known to be expressed in the 
enterocyte and the hepatocyte.  The transporters studied were OATP1A2, 1B1, 1B3, 
and 2B1.  We then utilized the analytical method developed in Specific Aim 1 to 
measure fexofenadine uptake in these systems. 
 
 To test whether fexofenadine was a substrate of OATPs expressed in the small 
intestine (OATP1A2, OATP2B1) or in the liver (OATP1B1, OATP1B3), I first used three 
concentrations of fexofenadine (1, 10, 100 µM) over a 10 minute time period  to see if 
any OATP-dependent uptake of fexofenadine was observed.  OATP1A2 transported 50-
150 times more fexofenadine than OATP2B1 at all concentrations tested; and while 
uptake seemed to increase with concentration for OATP2B1, the absolute level was too 
low to determine kinetic parameters. This result suggested that OATP2B1 may not be a 
major contributor to fexofenadine uptake system in enterocytes.  However, we were 
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able to characterize the effective fexofenadine transport by OATP1A2 in both time and 
concentration dependent manners, with a Km of 35 µM.  These findings support similar 
observations by Cvetkovic et al. (1999), Glaeser et al. (2007), and Shimizu (2005).  It is 
important to note however, that if expression levels of OATP2B1 were significantly 
greater than those of OATP1A2, transport of fexofenadine by OATP2B1 might play a 
more significant role in the disposition of fexofenadine in the small intestine than our 
results would indicate.  Based on the experiments presented in this dissertation and the 
central hypothesis of this project, OATP1A2 is a major transporter of fexofenadine and 
may play a dominant role in its disposition. 
 
 Similarly, to test fexofenadine uptake by OATP1B1 and OATP1B3, I first used 
three concentrations of fexofenadine (1, 10, 100 µM) over a 10 minute time period  to 
see if any liver specific OATP-dependent uptake of fexofenadine was observed.  
OATP1B1 was capable of fexofenadine transport, as was OATP1B3, however, 
OATP1B3 transported at least three times more fexofenadine at all concentrations 
tested.  Since fexofenadine was dosed orally as part of the Kansas Cocktail and our 
central hypothesis assumes the fexofenadine-drug interaction is occurring at an OATP 
in the small intestine, we did not explore OATP1B1, OATP1B3 and fexofenadine 
transport by hepatocytes any further in this dissertation. 
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7.4: Specific Aim 3 
 Based on observations in a previous clinical study, a decrease in fexofenadine 
Cmax and AUC occurs when fexofenadine is dosed with the CYP probes buspirone, 
caffeine, dextromethorphan, fexofenadine, losartan as part of the Kansas Cocktail.  In 
Specific Aim 2, we characterized the kinetics of fexofenadine transport by OATP1A2 
and acknowledged its importance in the disposition of orally dosed fexofenadine.  In 
Specific Aim 3, the goal was to characterize which of the probe drugs interacted with 
fexofenadine at OATP1A2. Recapitulation of the fexofenadine-drug interaction seen in 
human subjects in this cell-based model system provides further support for the identity 
of the dominant uptake transporter controlling fexofenadine pharmacokinetics. 
 
 An initial screen of OATP1A2-expressing HEK293 cells showed that 
fexofenadine, buspirone, dextromethorphan, and losartan were each capable of 
inhibiting transport of 0.1 µM estrone-3-sulfate in a concentration dependent manner.  
However, only losartan inhibited transport of 0.1 µM estrone-3-sulfate transport by 
OATP2B1.  Modulation of model substrate transport allowed us to elucidate which 
probe drugs may be inhibiting fexofenadine transport in the small intestine and explain 
our in vivo observations with fexofenadine and the Kansas Cocktail.   
 
 Additional studies demonstrated that losartan, dextromethorphan, and buspirone 
each inhibited transport of fexofenadine by OATP1A2 in a concentration-dependent 
manner.  The efficient transport of fexofenadine by OATP1A2 suggests that the activity 
117 
 
of this transporter may be a major determinant of the pharmacokinetics of orally dosed 
fexofenadine.  Furthermore, the inhibition of OATP1A2-dependent transport of 
fexofenadine by three of the drugs in the Kansas Cocktail is consistent with the 
decrease in fexofenadine bioavailability seen in the clinical study.  Net fexofenadine 
transport and the replication of the fexofenadine-probe drug interaction in this model 
system supports the conclusion in Specific Aim 3 that OATP1A2 is the major uptake 
transporter for fexofenadine absorption, and suggests that fexofenadine interacts with 
multiple probe drugs. 
 
 Based on the fexofenadine-CYP probe drug interactions we have characterized, 
the use of fexofenadine as a probe drug in conjunction with these probes for CYP 
activity is not recommended.  OATPs have wide, overlapping substrate specificity and 
are not inhibited or stimulated by any one endogenous compound, xenobiotic, or 
pharmaceutical drug.  Fexofenadine itself is a substrate of multiple OATPs and P-
glycoprotein, as well as being a part of numerous drug-drug and drug-diet interactions 
outside the clinical interaction presented as part of this dissertation.  Inclusion of 
fexofenadine in a probe drug cocktail would require validation that there were no 
significant pharmacokinetic interactions between each CYP probe and fexofenadine, 
since this would result in fexofenadine kinetics that were already altered and thus would 
greatly complicate the assessment of the affects of additional drugs or dietary factors on 
transporter function.. 
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 Interestingly, when we did the screens for modulation of model substrate activity 
by the probe drug cocktail with estrone-3-sulfate and OATP1A2 and OATP2B1, we also 
included screens for OATP1B1 and OATP1B3 as well as inclusion of a second 
substrate (estradiol-17β-glucuronide).  When examining the effects of each probe drug 
on transport of estrone-3-sulfate or estradiol-17β-glucuronide by each OATP, only 
losartan at 10 or 100 µM was capable of significant inhibition of model substrate 
transport.  This indicated that losartan had the potential to be transported by multiple 
enterocyte- and hepatocyte-specific OATPs that may play a role in the disposition of this 
orally dosed drug. 
 
Based on these observations, we hypothesized that both enterocyte and 
hepatocyte-specific OATPs are involved in the uptake and disposition of losartan.  We 
tested this hypothesis by characterizing losartan uptake using OATP1A2, OATP2B1, 
OATP1B1, and OATP1B3 expressing cell lines and determined the kinetics of losartan 
transport by 4 OATPs.  For OATP1A2, a Km of 58 µM was determined for losartan 
uptake and a Km of 16.6 µM for OATP2B1-expressing cells.  Based on these values, it 
appears that OATP2B1 has a greater affinity for losartan and may be responsible for 
uptake of orally dosed losartan in enterocytes.  OATP1B1 has a Km of 3 µM for uptake 
of losartan, with OATP1B3 having a Km of 17.6 µM for losartan.  In the hepatocyte, 
OATP1B1 appears to have a greater affinity for losartan and may be responsible for the 
uptake of this drug into the liver where it is metabolized by CYP2C9 into E3174.  This 
then implies that if drug-drug interactions involving OATP transport of losartan were to 
occur, it would more likely be at the OATPs with the higher affinity for losartan.  
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Therefore OATP2B1 and/or OATP1B1 would be sites for drug-drug interactions based 
on greater affinity for losartan.  However, since substrate specificity varies between 
OATPs as well as overlaps, assessing drug-drug interactions with losartan may require 
multiple substrates. 
 
7.5: Specific Aim 4 
 In Specific Aims 2 and 3, we explored the transport of fexofenadine by various 
OATPs and assessed in vitro the effects of three probe drugs (buspirone, 
dextromethorphan, losartan) from the Kansas Cocktail on fexofenadine transport by 
OATP1A2.  In Specific Aim 4, I explored the effect of OATP1A2 genotypes on 
fexofenadine-probe drug interactions.  Using three known human single nucleotide 
polymorphisms of OATP1A2, I used site-directed mutagenesis to create these variants 
of OATP1A2 (Ile13Thr, Arg168Cys, and Glu172Asp).  After verifying their sequences, a 
transfected HEK293 cell system was used to determine the effects of these mutations 
on the transport of fexofenadine via OATP1A2 as well as the effects of the other probe 
drugs on fexofenadine transport. 
 
 Previous observations of OATP1A2 single nucleotide polymorphisms indicate 
that variants of OATP1A2 have altered transport of multiple substrates, therefore we 
tested Ile13Thr, Arg168Cys, and Glu172Asp with regards to their ability to transport 0.1 
µM 3H-estrone 3-sulfate and 30 µM fexofenadine as compared to wild-type OATP1A2.  
The Ile13Thr mutant was reported to be a hyperfunctional OATP1A2 with regards to 
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estrone-3-sulfate and MTX transport, however, in our system, we see no increase in 30 
µM fexofenadine transport above that seen with wild-type OATP1A2.  Both Arg168Cys 
and Glu172Asp mutants were reported to be hypofunctional OATP1A2 with regards to 
estrone-3-sulfate and MTX transport, and we found that they also exhibit reduced 
transport of 30 µM fexofenadine when compared to wild-type OATP1A2.  Each mutant 
transports estrone-3-sulfate in a manner previously reported by Badagnani et al. (2006). 
 
 In Specific Aim 3, three components of the Kansas Cocktail were capable of 
inhibiting fexofenadine transport by WT OATP1A2.  Losartan was capable of significant 
inhibition of 30 µM fexofenadine transport by WT OATP1A2 at 10 and 100 µM 
concentrations of losartan; however, introduction of the hyperfunctional Ile13Thr variant 
does not alter the inhibition of fexofenadine transport in comparison to WT OATP1A2 
expressing cells.  Hypofunctional variants Arg168Cys and Glu172Asp transport less 
fexofenadine overall, therefore their percent inhibition by 10 and 100 µM losartan 
appears greater than it is in reality is since Arg168Cys transports approximately 50% 
less fexofenadine than wild-type and Glu172Asp transports 75% less fexofenadine than 
wild-type.  Taken together, the introduction of OATP1A2 mutations does not seem to 
alter the fexofenadine-losartan interaction seen previously.  Similar phenomena are 
seen with dextromethorphan and buspirone; their presence inhibits fexofenadine 
transport by all three OATP1A2 variants, but does not significantly change the nature of 
the interaction when a polymorphism is present. 
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 While the mutants functioned as intended with regards to fexofenadine transport, 
presence of the mutation did not alter the observed drug-drug interactions seen 
previously with OATP1A2 and components of the Kansas Cocktail.  Taking these data 
into account, it appears that the fexofenadine-drug interaction seen previously is a result 
of a direct drug-drug interaction and not a single nucleotide polymorphism. 
 
7.6: Future Directions 
 
7.6.1: Allosteric Activation of P-glycoprotein 
 
 The studies presented in this dissertation demonstrate that fexofenadine is 
transported by OATP1A2, and more importantly that three components in the Kansas 
Cocktail (buspirone, dextromethorphan, and losartan) are capable of significantly 
inhibiting OATP1A2-mediated transport of fexofenadine.  Transporters play a key role in 
fexofenadine disposition and the observed pre-systemic fexofenadine-drug interaction 
seen clinically.  The inhibition of OATP1A2-dependent fexofenadine transport by three 
of the CYP probe drugs used in the clinical study provides a plausible mechanism for 
the observed interaction. The alternative hypothesis, however, is that the observed 
fexofenadine-drug interaction is due to allosteric activation of P-glycoprotein by a 
component of the Kansas Cocktail.  Based on our findings reported here, it is 
reasonable to interpret decreases in both Cmax and AUC of oral fexofenadine, in the 
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absence of changes in clearance, as a result of OATP1A2 inhibition.  On the other 
hand, stimulation of P-gp would give the same result and such allosteric stimulation has 
been previously reported (Parasrampuria et al., 2001).  However, P-gp inhibition is more 
widely documented as a drug-drug interaction (Wang et al., 2002; Dresser et al. 2003, 
Kamath et al. 2005, Yasui-Furukori et al. 2005, Shimizu et al., 2006) resulting in an 
increased Cmax and AUC for fexofenadine. 
 
 It is important, however, to assess the role of P-glycoprotein in the efflux 
transport of fexofenadine and assess the impact that the CYP probes have on 
fexofenadine transport by P-glycoprotein.  Utilizing a similar initial screening of the 
effects of each probe drug on P-gp efflux of a model substrate (like Rhodamine 123), 
we could quickly and efficiently see which probe drugs may be modulating P-gp activity.  
Then, using an inside out membrane vesicle system, we could measure fexofenadine 
transport by P-glycoprotein and test which probe drugs are capable of altering P-
glycoprotein transport of fexofenadine.  If any components of the Kansas Cocktail are 
allosterically stimulating P-gp, we should observe an increase in fexofenadine transport 
in the presence of probe drugs.  Similarly to our single nucleotide polymorphism study 
with OATP1A2, we could also explore the effects of P-glycoprotein variants on transport 
activity of fexofenadine and whether a variant of P-glycoprotein could further enhance or 
inhibit transport of fexofenadine when dosed with the other Kansas Cocktail probe 
drugs. 
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7.6.2: Kansas Cocktail Human Subject Genotyping and OATP expression levels 
 
 Not all subjects showed the same fexofenadine-drug interaction when 
administered the full cocktail. In fact, about half of the subjects exhibited 50-75% 
decreases in fexofenadine Cmax and AUC from the cocktail, compared to the same 
dose of fexofenadine given alone, while the other half showed little effect. My fourth 
specific aim focused on the potential for genetic polymorphisms in OATP1A2 altering 
the susceptibility to these fexofenadine-probe drug interactions. The subjects from the 
original study could be re-consented and then genotyped for OATP1A2 to determine if 
the population sampled for this study matches those polymorphisms chosen.  There is 
significant probability that the polymorphisms examined in Specific Aim 4 are not the 
correct variants due to not knowing the genotypes of our sample population.  The ability 
to know and utilize each individual OATP1A2 genotype would allow us to more carefully 
examine the effect of inter-individual variation on the fexofenadine-drug interaction 
observed clinically.  Studies by both Lee et al. (2005) and Badagnani et al. (2006) report 
novel OATP1A2 mutations when screening their clinical populations.  The possibility 
that our subjects either overlap in genotype or present with a new single nucleotide 
polymorphism could explain some of the in vivo observations with the Kansas Cocktail. 
 
 Ideally, it would also be important to look at individual expression levels of 
OATPs and P-glycoprotein in our subjects.  The ability to biopsy the small intestine of 
each subject could provide very real and relevant data on OATP1A2 and OATP2B1 
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expression levels in the gut.  Based on our kinetic data from Specific Aim 2, we see a 
greater contribution of OATP1A2 to the disposition of oral fexofenadine versus that of 
OATP2B1 based on Km values and fold differences in transport.  However, if OATP2B1 
was expressed at much higher levels, that contribution could change.  Knowing the 
expression level of OATP1A2, OATP2B1, and even P-glycoprotein for each individual 
would indicate the precise location of this fexofenadine-drug interaction and give a 
possible indication to as to whether expression levels play a role in this observation.  If 
single nucleotide polymorphisms do not affect the observed fexofenadine-drug 
interaction, variation in wild-type expression levels may alter the observed interaction, 
explaining why 50% of the population experiences decreased AUC, whereas the other 
50% have baseline or increased AUC after dosing with the probe drug cocktail. 
 
 Further studies, like those described above, will fully elucidate the nature of the 
fexofenadine-drug interaction seen with the Kansas Cocktail and will clearly define the 
mechanism by which we see a substantial decrease in fexofenadine AUC when dosed 
as part of a probe drug cocktail.  Understanding the nature of this interaction and the 
roles OATPs and P-glycoprotein play in fexofenadine transport and disposition will also 
define the role of fexofenadine as a potential probe drug for transporters. 
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